Doctor of Philosophy by Austin, Sharon
 RISK FACTORS IMPACTING COLON AND/OR COLORECTAL CANCER  
 
MORTALITY AMONG AMERICAN INDIANS/NATIVE AMERICANS  
 















A dissertation submitted to the faculty of 
The University of Utah 















Department of Family and Preventive Medicine 
 
The University of Utah 
 
May 2014 
 Copyright © Sharon Austin 2014 
 
All Rights Reserved 








The dissertation of Sharon Austin 
has been approved by the following supervisory committee members: 
 
Stephen C. Alder , Chair 3/18/2014 
 
Date Approved 
Antoinette M. Stroup , Member 3/18/2014 
 
Date Approved 
Christina A. Porucznik , Member 3/18/2014 
 
Date Approved 
Joseph L. Lyon , Member 3/18/2014 
 
Date Approved 




and by Stephen C. Alder , Chair/Dean of  
the Department/College/School of Family and Preventive Medicine 
 






 Risk factors for colon (or colorectal) cancer mortality for American 
Indians/Alaska Natives (AI/AN) has been understudied. This project’s overall aim is to 
determine colon and colorectal cancer risk factors among AI/AN. Colorectal cancer risk 
factors from the literature were determined utilizing systematic review methods. 
Comorbidities, travel times to screening and treatment, were also explored as risk factors 
for colon cancer mortality using cox proportional hazards modeling to determine hazard 
ratios. The systematic review revealed that race was the only risk factor explored for 
colon or colorectal cancer among AI/AN, whereas numerous colon or colorectal cancer 
risk factors have been explored for Non-Hispanic Whites (NHW). Next was examining 
risk for colon cancer mortality by building models. An increasing Charlson comorbidity 
index had higher risk for mortality among NHW. Models examining travel times that 
were race specific resulted in greater risk for AI/AN and mortality for those having to 
travel longer to a chemotherapy facility. Longer travel time to a screening facility 
increased NHW risk for mortality. NWH increased travel time to a surgical center had a 
decreased risk for mortality. The regional and distant stage model showed that AI/AN 
living a distance from chemotherapy had increased risk for mortality. For NHW, living a 
distance from a screening facility had increased mortality. The all stage model for NHW 
showed that living further to a screening facility increased mortality risk but living 
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There is little known about colon cancer survivorship among American 
Indians/Alaska Natives (AI/AN). More specifically, risk factors that inhibit survival are 
largely unknown in the AI/AN population. Less is known about how travel to treatment 
and screening impacts colon cancer survival among AI/AN and NHW. In order to 
develop effective programs to improve survival, the area of colon cancer survivorship 
must be explored to a fuller extent.  
 
Colorectal Cancer Survival Among AI/AN compared to Whites/NHW 
 Many of the studies focus on colorectal cancer rather than only colon cancer. 
Colorectal cancer (CRC) survival among AI/AN has been examined for various regions 
of the United States but on a limited basis. Past studies have found that CRC survival 
among AI/AN is lower than Whites/NHW in a number of SEER locations.1-3 During the 
time period of 1975-1987, Clegg reported that White men (50.5%) and women (49.0%) 
had a greater probability of survival than AI/AN males (37.9%) and females (41.5%).1 
Similar results were found during the 1988-1997 time period, White males (59.1%) and 
females (59.7%) had higher survival than AI/AN males (58.0%) and females (46.1%).1  
Jemal, et al. also found similar results in terms of improved outcomes for 
Whites/NHW than AI/AN. The survival difference for White men was 1.7% and White
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women, 5.3%, for the 1992-2000 time period. White men (64.0%) and women (63.4%) 
had higher survival than AI/AN men (62.3%) and women (58.2%).2 The Swan, et al. 
study, results were presented in a graph that demonstrated higher survival for NHW than 
AI/AN for the time period 1988-1997.3  
In comparison to NHW, AI/AN colorectal cancer survival was lower in 
Arizona/New Mexico and Western Washington State.4,5 The Arizona/New Mexico data 
demonstrated higher 5-year survival for Whites (53.1%) than AI/AN (38.0%), which is a 
15.1% difference.4 As for Western Washington State data, there was a 7.6% survival 
difference, Whites/NHW (47.3%) having a higher probability of survival after diagnosis 
than AI/AN (39.7%).5  
Temporal analysis of survival has been improving for AI/AN but there is still a 
lag in survival; poorer outcomes among AI/AN persist across time periods with 
differences being more apparent among women than the men.1  
Past studies varied in terms of statistical significance when examining whether 
AI/AN had increased risk for all-cause, colon, or colorectal cancer mortality.1,2,5,6 AI/AN 
showed an increased risk for all-cause and CRC mortality, but these findings were not 
significant.5,6 Two additional studies found increased risk for CRC cancer mortality 
among female AI/AN than female NHW.1,2 Risk for cancer survival may be inconclusive, 
but when examining life expectancy, rates per 100,000 are lower for American 
Indians/Alaska Natives (73.6) than Whites (77.7).7  
 
Stage at Diagnosis among AI/AN and Whites/NHW  
A major factor that affects survival is stage of disease at diagnosis and AI/AN are 
being diagnosed at later stages.1,2 One study compared two time periods (1975-1987 and 
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1988-1997) and found that AI/AN were diagnosed less at the localized stages for the 
latter time period. The study also found that AI/AN were diagnosed more frequently at 
regional stages than Whites. During 1975-1987, Whites (34.5%) were more likely to be 
diagnosed for localized stages than AI/AN (27.2%) and for 1988-1997, 37.6% of Whites 
were diagnosed at localized stages than 30.1% of AI/AN. For the 1975-1987 time period, 
there were more Whites (20.3%) than AI/AN (19.8%) being diagnosed for distal stages 
for colorectal cancer, but for 1988-1997, less Whites (19.5%) were diagnosed for distal 
stage colorectal cancer than AI/AN (24.4%).1 Another study found stage at diagnosis 
rates as more unfavorable for localized diagnosis for AI/AN than Whites for the 1996-
2000 time period.8   
A more recent study has found that there are fewer AI/AN being diagnosed at 
localized stages and being diagnosed at later stages for colorectal cancer than NHW 
across various regions in the United States.9 Accounting for stage and age at diagnosis, 
survival outcomes are still poorer among AI/AN than Whites.1-3,5 These past studies have 
accounted for age, tumor stage, and late stage diagnosis but demonstrate that survival is 
still an issue for AI/AN.  Factors, which affect survival among AI/AN, are still 
unexplained.   
 
Colorectal Cancer and Public Health 
Cancer in general is a public health concern for the AI/AN population as it is the 
second leading cause of death among the AI/AN population. CRC is the second leading 
cause of cancer death for AI/AN men and third leading cause of cancer death for AI/AN 
women.10 There are a number of potential primary prevention activities that can be 
implemented to prevent colorectal cancer. Epidemiologic studies show dietary factors (fat 
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and fiber) may influence the onset of CRC.11,12 Decreasing caloric intake to reduce body 
weight may also decrease CRC risk.  Intake of calcium, vitamins A, C, D, E, and 
selenium has been hypothesized to reduce cancer risk.13 Nonsteroidal anti-inflammatory 
drugs, particularly aspirin, are being investigated as a preventive measure to reduce the 
onset of CRC.14  
 
Rural and Urban Classifications and Survivorship 
Rural-urban classifications are often used as a proxy to measure various 
constructs in colorectal cancer studies. Rural-Urban classifications have been used to 
measure the following: access to providers, access to health care, access to screening, and 
risk for CRC.15-22  However, there is lack in the consistency in how ‘urban’ and ‘rural’ 
are defined and a lack of clarity in describing why the chosen measure of urban/rural is a 
good proxy for various constructs. The classification of rural and urban can be a fluid 
concept and is highly dependent on the constraints one applies. Thus, using rural-urban as 
a proxy may result in measuring a number of factors rather than one sole factor.  
When access to care is discussed, it is often referred to as an intangible concept; 
however, quantitative analysis necessitates a concrete measurement. For instance, rural-
urban definitions are often used in models to measure access to care. Examining the issue 
on a theoretical level, it would seem more logical to measure distance to treatment and 
screening to determine access rather than categorizing individuals into rural and urban 
categories as a proxy for access. However, it is unclear whether a rural-urban variable 
versus a distance variable is a more valid measure for access to CRC related care. 




Purpose of This Study 
The overall goal of this project is to determine factors that affect colon cancer 
survival among American Indians/Alaska Natives (AI/AN) compared to Non-Hispanic 
Whites (NHW). There are three specific aims to carry out the overall goal. 
 
Specific Aim 1 
Determine the research needs by reviewing the literature and identifying research 
gaps with respect to colorectal cancer survival among AI/AN. There have been few 
studies of colon cancer survival among AI/AN, so both colon and rectal cancer literature 
will be included. The majority of colorectal cancer studies report on epidemiologic 
measures, such as incidence and mortality, and have not investigated potential factors 
associated with colorectal cancer survival. The overall goal is to assess gaps in regards to 
colorectal cancer survival and offer recommendations for future research.   
 
Specific Aim 2 
Determine whether comorbidities1 as defined by the Charlson Comorbidity Index 
and race are associated with poor colon cancer survival. Individuals with comorbid 
conditions may not be eligible for aggressive treatment schedules because having a co-
morbid condition affects treatment decisions and can affect recovery. The hypothesis is 
that those with one or more comorbid conditions will have worse survival outcomes than 
those with no comorbid conditions, after controlling for confounders and adjusting for 
covariates. A second research hypothesis is that survival disparities among AI/AN 
compared to NHW will persist even when controlling for comorbidities.  
                                                
1 The Charlson Index includes the following comorbidities: prior myocardial infarct, presence of congestive heart failure, peripheral 
vascular disease, cerebrovascular disease, dementia, chronic pulmonary disease, connective tissue disease, ulcer disease, mild liver 
disease, diabetes, hemiplegia, moderate or severe renal disease, diabetes with end organ damage, any tumor, leukemia, lymphoma, 
moderate or severe liver disease, mestatic solid tumor, and AIDS. 
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Specific Aim 3 
Determine if geographic access and race are associated with poor colon cancer 
survival. Geographic access will be defined as travel times to treatment (chemotherapy, 
radiation, and surgery) and travel times to screening (colonoscopy and sigmoidoscopy). 
The research hypothesis of this aim is that those living 60 miles or more from a treatment 
or screening facility will have worse colon cancer survival outcomes than those having to 
travel less. A secondary research hypothesis is that AI/AN will have worse outcomes than 
NHW after adjusting for various controls.  
 
Methods 
The first aim uses systematic review methods to determine risk factors for 
colorectal cancer mortality and all-cause mortality among colorectal cancer patients. The 
second and third aims are both retrospective cohort studies. Cox Proportional Hazards 
modeling was used to determine the effect that comorbidities, geographic accessibility 
and race has on colon cancer survival. 
 
Summary 
 A more in-depth discussion about the methods used for each specific aim, results 
and conclusions can be found in Chapters 2, 3, and 4. Chapter 5 includes the overall 
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  CHAPTER 2 
 
COLORECTAL CANCER MORTALITY RISK FACTORS FOR  
AMERICAN INDIAN/ALASKA NATIVES:  
A SYSTEMATIC REVIEW 
 
Abstract 
 There have been few published studies about colorectal cancer (CRC) among the 
American Indian/Alaska Native (AI/AN) population. The studies that report on 
epidemiologic measures, such as incidence, mortality, and survival, among AI/AN have 
not fully investigated potential risk factors for mortality among those diagnosed with 
colorectal cancer. The overall goal is to assess knowledge gaps in CRC mortality risk 
factors among AI/AN by conducting a systematic review of the literature, comparing the 
AI/AN literature to what is known for Whites, and to offer recommendations for future 
research.  
 A systematic review was conducted in two phases. First, a search was conducted 
to find published systematic reviews in the area of risk factors for CRC mortality among 
adult AI/AN and White populations. A second search was conducted for primary 
literature on the same topic. 
 The results indicate that race was the only risk factor explored for AI/AN, 
whereas the literature for Whites and Non-Hispanic Whites explores a number of risk 
factors, which can be categorized into 6 groups: Demographic/Clinical, Lifestyle, Health
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System, Treatment, Tumor Biology, and Genetic Factors. The gap in knowledge of 
known or suspected risk factors that contribute to risk between AI/AN and Whites/NHW 
demonstrate the need for more research. 
 
Introduction 
Cancer is a public health concern for the American Indian/Alaska Native (AI/AN) 
population because it is the second leading cause of morbidity and mortality for AI/AN 
men and women.1-3 Cancer mortality in general has been examined in various regions of 
the United States among AI/AN but on a limited basis; and even fewer studies that 
examine risk for colorectal cancer (CRC) mortality among AI/AN. Previous studies 
suggest risk for CRC mortality among AI/AN to be greater than Whites or Non-Hispanic 
Whites (NHW).4-8 A temporal analysis also demonstrated greater risk for CRC mortality 
for AI/AN than NHW and worse outcomes for AI/AN women and men in comparison to 
their NHW counterparts.4 After controlling for stage and age at diagnosis, risk for CRC 
mortality is still greater for AI/AN than Whites.4-6,8 
There is a scarcity of AI/AN research that examines CRC survivorship and thus, 
there is a little information on risk factors that affect CRC mortality among AI/AN. The 
aims of this study are to: (1) conduct a systematic review of the available literature that 
identifies risk factors for mortality among AI/AN and Whites and (2) conduct a 
comparison between the AI/AN and Whites to identify potential risk factors for further 
exploration, which will increase our understanding the burden of CRC among AI/AN. 
Cataloging the risk factors associated with mortality among AI/AN and NHW will guide 
the direction of future research to explain mortality patterns among AI/AN.  
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Methods 
A systematic review of the literature was conducted in two phases. The first phase 
searched for published systematic reviews in the area of risk factors for CRC mortality 
among adult AI/AN and White populations. The second phase involved a search for 
primary literature on the same topic.   
 
Systematic Review Search 
The search for reviews and meta-analyses were conducted in Medline and 
CINAHL for the White and AI/AN populations, and additionally, in the Native Research 
Database for the AI/AN population. If reviews were found, they were examined for topic 
and content and determined if the review needed to be updated or modified.9  
PubMed was the interface used to access Medline.  Medical Subject Headings 
(MeSH) and synonyms were used to find studies related to the topic.  PubMed uses 
MeSH terms to index articles and MeSH terms provide a consistent way to retrieve 
information.  MeSH terms for this study were developed using the National Library of 
Medicine’s MeSH database found in the PubMed Advance Search.  Synonyms were 
developed by the author and also McKibbon.10 See Table 2.1 for MeSH terms and 
synonyms.  
In conjunction with the MeSH terms and synonyms, the following algorithm was 
entered into the PubMed search window to find systematic reviews and meta-analysis 
articles: Meta-analysis[pt] OR Meta-anal*[tw] OR Metaanal*[tw] OR quantitativ* 
review* OR quantitative* overview*[tw] OR systematic* review* OR systematic* 
overview*[tw] OR methodologic* review* OR methodologic* overview*[tw] OR 
review[pt] AND medline[tw]. Two searches were conducted to find systematic review  
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articles.  An initial search used synonyms in conjunction with the algorithm and a second 
search used MeSH terms with the algorithm.  
The interface, EBSCO, was used to conduct searches in the CINAHL database, 
limiting searches specifically for "systematic reviews" and CINAHL Subject Headings. 
Synonyms were developed by the author and also by McKibbon.10 Table 2.1 provides 
CINAHL headings and synonyms used to find articles that reflect the topic. Two searches 
were conducted to find systematic review articles in the CINAHL database.  One search 
used synonyms and the other used subject headings; both methods were contained with 
the algorithm in conjunction with the two searches. 
The Native Research Database was utilized to search for systematic reviews for 
AI/AN. The MeSH term search only used the colorectal cancer study factor term, 
“colorectal neoplasm.”  There were very few AI/AN colorectal cancer articles and a more 
stringent search using all MeSH terms related to the topic areas would immediately 
eliminate all literature.  The same was true for synonyms.  Synonyms that were used for 
the colorectal cancer study factor were “colorectal cancer” and “bowel cancer.” Table 2.2 
lists the MeSH terms and synonyms for the search in the Native Research Database. 
 
Published Primary Literature Search 
The following databases were used to search for primary studies: Medline, 
CINAHL and the Native Research Database (AI/AN only). Search methodology mirrored 
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Native Health Database 
(MeSH Terms) 
Native Health Database 
(Synonyms) 
Population AI/AN Nonapplicable Nonapplicable 





Colorectal Neoplasm "Colorectal Cancer" 
"Bowel cancer" 
    
 Risk 
Factors 
Risk Factors Risk Factors 
    
Outcome Mortality Mortality “Cause of Death”10  
“Survival Rate”10 






“Survival” “Survival Rate”  





Inclusion criteria were as follows: studies that included a White population, AI 
population, AI/AN population, United States population, and published in English.  All 
publication years were included in the search. A population that was 18 years of age and 
over was also included in the selection of articles. Outcome for the studies were all-cause 
mortality, colon cancer mortality, and colorectal cancer mortality.  
Three of the studies included in this review used all-cause mortality as the 
outcome measure and they used various non-SEER data.11-13 Although there was no clear 
rationale behind choosing all-cause mortality instead of cancer-specific mortality, these 
studies were included in the review because their focus was CRC mortality. The results 
will have to be viewed as an approximation for colon and/or rectal cancer mortality.  
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Exclusion Criteria 
Exclusion criteria include studies with a solely Alaska Native focus and studies 
that focus on HNPCC, FAP, Peutz-Jeghers syndrome, Cowden's syndrome, and 
hereditary mixed polyposis.  
 
Quality Appraisal 
The author was the sole reviewer of the literature and was responsible for 
selecting and omitting studies. Dissertation committee members also gave input into 
whether particular articles should be included or not. Endnote X4 (Thomson Reuters, 
Philadelphia, PA) was used to de-duplicate articles.  
 
Literature Selection Results 
 The systematic review search for the White population retrieved one article by 
Berry, et al.14 The article by Berry, et al. reported on survival and colorectal screening 
proportions and also gave a descriptive report on cancer stage, colorectal cancer 
screening, and colorectal cancer treatment. Since the article did not report on risk factors 
for CRC, it was excluded.  
The search for primary articles in Medline and CINAHL retrieved 221 articles, of 
which 16 articles were included in the final review. No articles were reviewed in the 
search for AI/AN systematic reviews.  The search for primary articles resulted in 4 
articles for the final review (Table 2.3).  
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PubMed: Synonyms 0 46 0 6 
PubMed: MeSH 1 243 0 14 
CINAHL: 
Synonyms 
0 0 0 1 




N/A N/A 0 18 
Native Health 
Database: MeSH 
N/A N/A 0 14 
Total after de-
duplication  
1 221 0 32 




AI/AN Risk Factors  
 The search for AI/AN primary articles resulted in four articles4,5,15,16 which had 
very limited information in regards to risk factors for CRC survival. Interestingly, the 
relevant literature revealed that race defined as AI/AN was the only risk factor explored 
(Table 2.4). Studies suggest that the risk for all-cause and CRC mortality is higher among 
the AI/AN than the NHW population. Results also demonstrated that AI/AN are at higher 
risk for CRC mortality than NHW when diagnosed at later stages15. There appears to be 
no difference in CRC mortality risk between AI/AN in the early stage group (HR=1.20, 
CI=0.90-1.80) than the later stage group (HR=1.20, CI=1.00-1.40)15. Studies also suggest 
that AI/AN men and women have a higher risk for CRC mortality than their NHW 
counterparts,4,5 with CRC mortality risks among AI/AN men and women ranging from 
10% -14% and 38% - 50% higher than for NHW men and women, respectively4,5.  These
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Table 2.4: Race as a Risk Factor for Colorectal Cancer and All-Cause Mortality among American Indians/Alaska Natives 
Study Model Stratification 
Variable 















1.30 (1.00, 1.60) 
 





Age, stage, and sex. 
        
bChien, et 
al. [2005]15  
 
1  Race NHW 
AI 
1.00 
1.20 (1.00, 1.40) 
120,491  
437 
Age at diagnosis, year of diagnosis, 
SEER registry, surgical treatment (Y/N), 
radiation treatment, stage at diagnosis, 
and Tumor Stage. 
        
 2 Tumor Stage 




1.20 (0.90, 1.80) 
68,641  
220 
Age at diagnosis, year of diagnosis, 
SEER registry, surgical treatment (Y/N), 
radiation treatment, and stage at 
diagnosis. 
        
 3 Tumor Stage 




1.20 (1.00, 1.40) 
51,850  
217 
Age at diagnosis, year of diagnosis, 
SEER registry, surgical treatment (Y/N), 
radiation treatment, and stage at 
diagnosis. 
        
bClegg, et 
al. [2002]4  
1 Sex: Males Race NHW 
AI/AN 
1.00 
1.10 (0.86, 1.50) 
95,455  
259 
Age and tumor stage 
        
 2 Sex: Females Race NHW 
AI/AN 
1.00 
1.50 (1.10, 1.90) 
95,313  
222 




Table 2.4: continued 
Study Model Stratification 
Variable 




Variables Adjusted for in Model 
bJemal, et 
al. [2004]5   
1 Sex: Males Race NHW 
AI/AN 
1.00 
1.14 (0.95, 1.35) 
No.c Age and tumor stage. 
        
 2 Sex: Females Race NHW 
AI/AN 
1.00 
1.38 (1.16, 1.64) 
No.c Age and tumor stage. 
aResults are for all-cause mortality     
bResults are for colorectal cancer mortality 





findings suggest that like NHWs, race, sex, and stage are potential risk factors for all-
cause/CRC mortality among the AI/AN population. 
 
White/NHW Risk Factors 
Risk factors for mortality among the White population have been explored more 
extensively than the AI/AN population. Risk factors, based on the literature, for mortality 
among the White population can be grouped into 6 general categories: 
demographic/clinical factors, lifestyle factors, health system factors, treatment factors, 
tumor biology factors, and genetic factors (Table 2.5).   
 
Demographics and Clinical Factors 
 The majority of the studies, which examined racial disparities, concluded that the 
White population is at lower risk for CRC, colon, and all-cause mortality than African 
Americans (Table 2.6).11,13,17-21 Risk for CRC, colon, or all-cause mortality for the White 
population ranged from 40% to 88% less than African Americans. Results are mixed for 
Hispanic groups as the literature shows both an increased and decreased risk for CRC and 
all-cause mortality for Hispanics when compared to Whites.13,22,23 The data suggest that 
Pacific Islander men and women have lower risk for CRC mortality than the White 
population.22 However, the results were not statistically significant. One study compared 
survival outcomes between Filipino-Americans, Philippine population, and Whites.24 The 
results found that Non-Hispanic Whites (HR=1.12, CI=1.04-1.20) and the Philippine 
population (HR=2.30, CI=1.83-2.25) had higher risk for CRC mortality than Filipino- 
Americans.24  




Table 2.5: Categorization of Colorectal Cancer Mortality Risk Factors for the 
White/NHW Population 
Category Risk Factors 
Demographic/Clinical 
Factors 
Race, Age, Sex, Year of Diagnosis, SEER Region, Education 
Level, Poverty Index/Status, Median Income, SES (Income & 
Education), Marital Status, Urban/Rural Residence, Bowel 
Obstruction, and Comorbidities 
  




Insurance Type, Facility Type 
  
Treatment Factors First Course Therapy, Surgery, Standard Therapy Received, 





SEER1 Summary Stage, TNM Stage, TNM Staging 
Components, Cancer Site, Cancer Size, Histology or 
Morphology, Tumor Differentiation, Histological Grade 
  
Genetic Factors GSTM1 Gene, GSTT1 Gene, GSTP1 Gene, Codon 72 
Polymorphisms, Bcl-2 Expression, P53 Status, Nuclear 







	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1 Surveillance Epidemiology and End Results Program 
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Table 2.6: Race as a Predictor for Colorectal and Colon Cancer and All-Cause Mortality among White/NHW and Other Populations 
Study Model Stratification 
Variable 




Variables Adjusted for in Model 
aAlexander, et 
al. [2004]17   






Age, gender, hospital, tumor stage, 
degree of tumor differentiation, 
tumor anatomic subsite, and anatomic 
tumor site.  
        





  72 
Age, gender, hospital, tumor grade, 
anatomic subsite in the colon. 
        




  88 
  54 
Age, gender, hospital, tumor grade, 
anatomic subsite in the colon. 
        




  38 
  32 
Age, gender, hospital, tumor grade, 
anatomic subsite in the colon. 
        
aAlexander, et 
al. [2005]18    
1 Low Grade 
Tumor 






Race, age, gender, treatment hospital, 
tumor anatomic subsite, pathologic 
tumor stage, tumor grade, and race X 
tumor grade interaction. 
        
 2 High Grade 
Tumor 




  39 
  26 
Race, age, gender, treatment hospital, 
tumor anatomic subsite, pathologic 
tumor stage, tumor grade, and race X 
tumor grade interaction. 
        
bGovindarajan, 
et al. [2003]11    
  Race White  
AA 
1.00 






Table 2.6: continued 
Study Model Stratification 
Variable 




Variables Adjusted for in Model 
Jones, et al. 
[2009]25 
 
1  Race White  
AA 
1.00 
1.85 (1.18, 2.91) 
184 
131 
Age, gender, TNM stage at diagnosis, 
self-rated health, smoking status, and 
receipt of chemotherapy.  
        
 2  Race White  
AA 
1.00 
1.82 (1.15, 2.89) 
117 
  74 
Age, gender, TNM stage at diagnosis, 
self-rated health, smoking status, 
receipt of chemotherapy, and GSTM1 
genotype. 
        
 3  Race White  
AA 
1.00 
1.79 (1.13, 2.84) 
120 
  76 
Age, gender, TNM stage at diagnosis, 
self-rated health, smoking status, 
receipt of chemotherapy, and GSTT1 
genotype. 
        
 4  Race White  
AA 
1.00 
1.89 (1.21, 2.98) 
116 
  77 
Age, gender, TNM stage at diagnosis, 
self-rated health, smoking status, 
receipt of chemotherapy, and GSTP1 
genotype. 
        
Marcella, et al. 
[2001]19   
  Race White  
AA 
1.00 
1.19 (1.09, 1.30) 
58,020 
  2,784 
Age, gender, sex, race X sex 







Table 2.6: continued 
Study Model Stratification 
Variable 




Variables Adjusted for in Model 
aMayberry, et 
al. [1995]20   






Education, poverty index, type of 
insurance, number of comorbid 
conditions, bowel obstruction, 
anatomic site, grade, histology, 
nuclear atypia, summary staging, 
primary tumor status, node positivity, 
distant metastasis, and surgery. 
        
Niu, et al. 
[2010]22 
 





1.13 (1.02, 1.25) 
0.99 (0.78, 1.26) 






        





1.15 (1.04, 1.26) 
0.84 (0.64, 1.10) 
0.95 (0.84, 1.08) 
26,291 
  2,924 
     289 
  1,357 
Poverty status. 
        
Potosky, et al. 
[2002]23  




0.94 (0.55, 1.04) 
0.84 (0.37, 1.11) 
 16 
171 
    9 
Standard therapy received, year of 
diagnosis, age at diagnosis, sex, 
SEER region, marital status, median 
income, cancer site, tumor extent, 





Table 2.6: continued 
Study Model Stratification 
Variable 




Variables Adjusted for in Model 
















1.12 (1.04, 1.20) 





Age, sex, stage, morphology, surgery, 
and radiotherapy. 











1.18 (1.01, 1.37) 
1.11 (0.97, 1.27) 





Age, sex, marital status, insurance 
payer medicare, insurance payer non-
medicare, education level, median 
income level, place of residence, 
anatomic site, comorbidity index, 
smoking status, stage at diagnosis, 
and treatment modality. 
        
Yan, et al. 
[2009]21 
  Race White 
AA 
1.00 
1.06 (0.94, 1.19) 
7,215 
1,863 
Age, sex, marital status, 
socioeconomic status, tumor grade, 
TNM stage, and surgical treatment.  
aResults are for colon cancer mortality     
bResults are for all-cause mortality 
cModel 1: covariates include age, gender, TNM stage at diagnosis, self-rated health 
dModel 1 + GSTM1 genotype 
eModel 1 + GSTT1 genotype 








White population had lower risk for colon cancer mortality than African Americans.17,18 
At Stage II, III, or IV, the White population’s risk for colon mortality was 40% to 83% 
lower than African Americans.17 The White population (HR=1.00) also had lower risk by 
high tumor grade for colon cancer mortality than African Americans (3.05, CI=1.32-
7.05).18 White males and females have lower risks for CRC mortality than their African 
Americans counterparts (Males: HR=1.13, CI=1.02-1.25; Females: HR=1.15, CI=1.04-
1.26).22  
The studies that included sex as a predictor found males to be at higher risk for 
all-cause and CRC mortality than women (Table 2.7). Three of the six studies examining 
sex had results that were statistically significant,13,19,22 ranging from HR=0.84 (CI=0.78- 
0.92) to HR=0.92 (CI=0.86-0.99) for all-cause and CRC mortality.  
 Studies that examined marital status found that those who are married were at 
10% to 21% less risk for mortality than those who are not married (Table 2.8).13,21 Age as 
expected, a predictor for mortality with older patients, having higher risk for CRC, colon, 
and all-cause mortality (Table 2.9).  
 A number of studies included at least one measure of socio-economic status (SES) 
as a predictor for mortality. Reporting risks for mortality using measures of education, 
income, and employment status (Table 2.10). The majority of the results for income as a 
risk for all-cause, CRC, or colon mortality were not statistically significant.12,13,20,22,23 
However, the results suggest that the poorer one is, the greater risk for CRC, colon, and 
all-cause mortality.12,13,20,22,23 The data also suggest that men and women who fall at or 




Table 2.7: Sex as a Predictor for Colorectal Cancer and All-Cause Mortality among the White/NHW Population 
Study Model Stratification 
Variable 








  Sex Male 
Female 
1.00 
0.91 (0.88, 0.94) 
31,012 
30,792 
Age, race, gender, race X sex interaction 
term, stage, anatomic site, grade, education. 
        
Pagano, et 
al. [2003]26  






Stage at diagnosis, age, and year of 
diagnosis. 






Stage at diagnosis, age, and year of 
diagnosis. 






Stage at diagnosis, age, and year of 
diagnosis. 
        
Potosky, et 
al. [2002]23  
 
  Sex Male 
Female 
1.00 
0.86 (0.70, 1.06) 
106  
94 
Standard therapy received, year of diagnosis, 
age at diagnosis, race, SEER region, marital 
status, median income, cancer site, tumor 
extent, nodal status, histologic grade, and 
comorbidities. 
        
Redaniel, et 
al. [2010]24  
 
  Sex Male 
Female 
1.00 
1.00 (0.98, 1.01) 
69,273 
68,584 
Age, race, stage, morphology, surgery, and 
radiotherapy. 





  Sex Male 
Female 
1.00 
0.92 (0.86, 0.99) 
4,875 
4,673 
Age, race, marital status, insurance payer 
medicare, insurance payer nonmedicare, 
education level, median income level, place 
of residence, anatomic site, comorbidity 





Table 2.7: continued 
Study Model Stratification 
Variable 




Variables Adjusted for in Model 
Yan, et al. 
[2009]21  
 
  Sex Male 
Female 
1.00 
0.84 (0.78, 0.92) 
4,666  
4,412 
Age, race, marital status, socioeconomic 
status, tumor grade, TNM stage, and surgical 
treatment. 
aResults are for all-cause mortality 







Table 2.8: Marital Status as a Predictor for Colorectal Cancer Mortality among the White/NHW Population 




Variables Adjusted for in Model 









1.24 (1.00, 1.54) 
121 
79 
Standard therapy received, year of diagnosis, age at 
diagnosis, race, sex, SEER region, median income, 
cancer site, tumor extent, nodal status, histologic 
grade, and comorbidities. 
      













Age, sex, race, insurance payer medicare, insurance 
payer nonmedicare, education level, median income 
level, place of residence, anatomic site, comorbidity 
index, smoking status, stage at diagnosis, and 
treatment modality. 
      









1.26 (1.15, 1.37) 
4,963 
3,810 
Age, sex, race, socioeconomic status, tumor grade, 
TNM stage, and surgical treatment. 
 




Table 2.9: Age as a Predictor for Colorectal and Colon Cancer and All-Cause Mortality among the White/NHW Population 
Study Model Stratification 
Variable 




Variables Adjusted for in Model 
Chatla, et al. 
[2005]27  
 
1 Stage II Age <65 
>=65 
1.00 
1.08 (0.36, 3.22) 
43 
49 
Gender, Bcl-2 expression, pT 
component of stage, tumor location, 
tumor differentiation, and tumor size. 
        





1.74 (0.70, 4.34) 
30 
36 
Gender, Bcl-2 expression, pN 
component of stage, pT component of 
stage, tumor location, tumor 
differentiation, and tumor size. 
        
bGovindarajan, 
et al. [2003]11  
  Age <60 
>=60 
1.00 
1.40 (1.10, 1.70) 
No.d Race and stage. 
        
aJessup, et. al. 
[2005]28  
 







1.19 (1.14, 1.25) 
1.56 (1.49, 1.62) 





Race, sex, histological grade, 
anatomic subsite, AJCC substage, 
surgery, and adjuvant chemotherapy. 
        
Manne, et al. 
[1998]29 
 
  Age <65 
>=65 
1.00 
2.86 (1.47, 5.60) 
230 
274 
Gender, tumor location, tumor size, 
differentiation, pT component of 
stage, pN component of stage, pM 
component of TNM stage, and 
nuclear accumulation of p53. 
        
Marcella, et al. 
[2001]19 
 






0.67 (0.58, 0.77)  
0.86 (0.82, 0.90) 
1.00 
1.42 (1.37, 1.47) 
No.d Race, gender, sex, race X sex 





Table 2.9: continued 
Study Model Stratification 
Variable 




Variables Adjusted for in Model 
Pagano, et al. 
[2003]26  
1 1960-1974 Age 10 yr. 
increments 
1.20c 2879 Stage, sex, and year of diagnosis. 
 2 1975-1987  10 yr. 
increments 
1.17c 5545 Stage, sex, and year of diagnosis. 
 3 1988-2000  10 yr. 
increments 
1.17c 8000 Stage, sex, and year of diagnosis. 
        
Potosky, et al. 
[2002]23  
 








0.59 (0.41, 0.83) 
0.58 (0.43, 0.79) 
0.54 (0.39, 0.74) 






Standard therapy received, year of 
diagnosis, race, age at diagnosis, sex, 
SEER region, marital status, median 
income, cancer site, tumor extent, 
nodal status, histologic grade, and 
comorbidities. 
        
Redaniel, et al. 
[2010]24  
 








1.04 (0.99, 1.09) 
1.28 (1.23, 1.34) 
1.75 (1.68, 1.83) 






Sex, stage, morphology, surgery, and 
radiotherapy. 
        
bRobbins, et al. 
[2009]12 
 







1.11 (1.03, 1.19) 
1.23 (1.15, 1.32)  





Insurance status, stage, facility type, 
neighborhood education level and 
neighborhood income level and 





Table 2.9: continued 
Study Model Stratification 
Variable 




Variables Adjusted for in Model 
bRoetzheim, et 
al [2000]13  
  Age  1.03 (1.025, 1.035) No.d Race, sex, marital status, insurance 
payer medicare, insurance payer non-
medicare, education level, median 
income level, place of residence, 
anatomic site, comorbidity index, 
smoking status, stage at diagnosis, 
and treatment modality. 
        
Yan, et al 
[2009]21  






1.17 (0.99, 1.39) 




Race, sex, marital status, 
socioeconomic status, tumor grade, 
TNM stage and surgical treatment. 
aResults are for colon cancer mortality     
bResults are for all-cause mortality 
cSignificant at the p<0.0001  











Table 2.10: SES Measures as Predictors for Colorectal and Colon Cancer and All-Cause Mortality among the White/NHW Population 
Study  Model Stratification 
Variable 




Variables Adjusted for in Model 
Potosky, et 
al. [2002]23  
 








1.14 (0.80, 1.49) 
0.92 (0.70, 1.21) 





Standard therapy received, year of 
diagnosis, race, age at diagnosis, 
sex, SEER region, marital status, 
cancer site, tumor extent, nodal 
status, histologic grade, and 
comorbidity. 















1.14 (0.80, 1.49) 
 
0.92 (0.70, 1.21) 
 







Insurance status, age, stage, 
facility type, neighborhood 
education level, and neighborhood 
income level and number of 
comorbidity. 





   Median Income 
Level 
 
0.99 (0.94, 1.03) No.c Age, race, sex, marital status, 
insurance payer medicare, 
insurance payer nonmedicare, 
education level, place of residence, 
anatomic site, comorbidity index, 
smoking status, stage at diagnosis, 






Table 2.10: continued 
Study  Model Stratification 
Variable 

















0.6 (0.4, 0.9) 
0.4 (0.3, 0.7) 





Education, race, type of insurance, 
number of comorbid conditions, 
bowel obstruction, anatomic site, 
grade, histology, nuclear atypia, 
summary staging, primary tumor 
status, node positivity, distant 
metastasis, and surgery. 
        
Niu, et al. 
[2010]22 
 








1.04 (0.97, 1.11) 
1.12 (1.03, 1.21) 





Race, age, and stage. 








1.05 (0.99, 1.13) 
1.07 (0.99, 1.16) 





Race, age, and stage. 














1.0 (0.7, 1.6) 
0.8 (0.6, 1.3) 







Education, race, poverty index, 
type of insurance, number of 
comorbid conditions, bowel 
obstruction, anatomic site, grade, 
histology, nuclear atypia, summary 
staging, primary tumor status, node 





Table 2.10: continued 
Study  Model Stratification 
Variable 




Variables Adjusted for in Model 
Robbins, et 
al. [2009]12  
 








1.14 (1.07, 1.22) 
1.14 (1.07, 1.22) 





Insurance status, age, stage, 
facility type, neighborhood 
education level and neighborhood 
income level, and number of 
comorbidities. 












Age, race, sex, marital status, 
insurance payer medicare, 
insurance payer nonmedicare, 
education level, median income 
level, place of residence, anatomic 
site, comorbidity index, smoking 
status, stage at diagnosis, and 
treatment modality. 





  SES 
 
Bottom Quartile 
of H.S. Grads 
Middle 2 
Quartiles of H.S 
Grads 
Upper Quartile 
of H.S Grads 
Unemployment 
>10% 
1.09 (1.04, 1.15) 
 





1.05 (1.00, 1.11) 
No.c Age, race, gender, sex, race X sex 
interaction term, stage, anatomic 




Table 2.10: continued 
Study  Model Stratification 
Variable 




Variables Adjusted for in Model 
Yan, et al. 
[2009]21  








1.19 (1.05, 1.35) 
1.12 (1.01, 1.25) 
 
 







Age, race, sex, marital status, 
tumor grade, TNM stage, and 
surgical treatment. 
aResults are for colon cancer mortality     
bResults are for all-cause mortality 














Less education was also found to be a significant predictor for increased all-cause 
mortality (Table 2.10), with risks being the largest in the neighborhood group that had the 
highest percentage of individuals without a high school degree.12 A combination of being 
employed, nonpoor and under-educated also a increases one’s risk for CRC mortality by 
12%.21 Yan, et al. found that the working poor who were under-educated had the highest 
risk for CRC mortality (H.R.=1.19, CI=1.05-1.35).21	  
 Residence and year of diagnosis as predictors for mortality among non-AI/AN 
were also not statistically significant (Table 2.11). However, the results suggest that risk 
for CRC mortality is higher in the regions of Connecticut (HR=1.04, CI=072-1.49), New 
Mexico (HR=1.15, CI=0.65-2.04), and Seattle (HR=1.23, CI=0.86-1.74) than in the other 
SEER regions.23 The Los Angeles SEER region (HR=0.80, CI=0.47-1.34) potentially has 
the least risk for mortality, followed by Iowa, Atlanta, and Utah. The lack of significance 
may be due to low sample size for each area.  
Urban and rural residency may also be an indicator for mortality. One study, not 
statistically significant, suggests that urban residents are at less risk (HR=0.98, CI=0.91-
1.05) for all-cause mortality than nonurban residents.13 The lack of rural-urban residence 
may be due to the statistical model having specific covariates that measure disparities. 
For instance, this model also included insurance status, income level, and education, 
which could be predictors for rural-urban status.   
The results from year of diagnosis were not statistically significant, but they 
suggest increased CRC mortality as the year of diagnosis increases.23,26 Again, low 
sample size may be the reason for nonsignificant results.  
Clinical predictors, such as bowel obstruction and comorbidity, can be found in
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Table 2.11: Other Predictors for Colorectal Cancer and All-Cause Mortality among the White/NHW Population 
Study Model Stratification 
Variable 




Variables Adjusted for in Model 
Potosky, et 
al. [2002]23  
 
















0.80 (0.47, 1.34) 
0.84 (0.60, 1.20) 
0.88 (0.56, 1.38) 
0.95 (0.62, 1.43) 
1.00 (0.73, 1.38) 
1.04 (0.72, 1.49) 
1.15 (0.65, 2.04) 












Standard therapy received, year of 
diagnosis, race, age at diagnosis, 
sex, marital status, median 
income, cancer site, tumor extent, 
nodal status, histologic grade, and 
comorbidity. 






 Residence Urban 
Non-urban 




Age, race, sex, marital status, 
insurance payer medicare, 
insurance payer non-medicare, 
education level, median income 
level, anatomic site, comorbidity 
index, smoking status, stage at 
diagnosis, and treatment modality. 
        









0.65b No.d Age, stage, and sex. 




0.87c No.d Age, stage, and sex. 




0.99c No.d Age, stage, and sex. 
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Table 2.11: continued 
Study Model Stratification 
Variable 




Variables Adjusted for in Model 
Potosky, et 
al. [2002]23  







0.85 (0.68, 1.06) 




Standard therapy received, race, 
age at diagnosis, sex, SEER 
region, marital status, median 
income, cancer site, tumor extent, 
nodal status, histologic grade, and 
comorbidity. 
aResults are for all-cause mortality 
bSignificant at the p<0.0001 
cNot significant at the p<0.005 








Table 2.12. Bowel obstruction was the only clinical characteristic that was examined as a 
predictor for mortality (Table 2.12).  Risk for colon cancer mortality was high if one had 
bowel obstruction or perforation and required emergency surgery compared to those who 
had no bowel obstruction (HR.=2.5, CI=1.6-4.2).20 
Various studies used different measures to examine the effect of comorbidity, 
including amount (number) of comorbidity and level of severity. Results indicate that 
having one comorbidity increases your risk for all-cause mortality by 12%, two 
comorbidity increases risk by 32%, three or more increases by 48%.12 Based on the 
Roetzheim’s study, which takes severity of diseases into account, one comorbidity 
increases risk for all-cause mortality by 22%, but increases to 52%.13	  	  
Lifestyle Factors 
Lifestyle factors can also impact colon cancer, colorectal cancer, or all-cause 
mortality. Only one study included a lifestyle factor to examine the impact on all-cause 
morality. Smoking status was the only lifestyle factor that was examined. After 
controlling for several variables, smoking status demonstrated a negative effect on 
survival.  Smokers are at a higher risk (HR=1.13, CI=1.03-1.24) for all-cause mortality 
than nonsmokers (Table 2.13).13  
 
Health System Factors 
In general, individuals who are uninsured or have public insurance are at higher 
risk for mortality than those with private insurance (Table 2.14).  In comparison to having 
private insurance, the uninsured had the greatest risk for all-cause mortality (41%) and 
colon cancer mortality (76%).12,13,20 Medicare recipients did not fair well in comparison 
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Table 2.12: Clinical Factors that Predict Colorectal and Colon Cancer and All-Cause Mortality among the White/NHW Population 
















1.80 (1.30, 2.40) 
2.50 (1.60, 4.20) 
 
0.80 (0.40, 1.60) 
No.c Education, race, poverty index, type of insurance, number 
of comorbid conditions, anatomic site, grade, histology, 
nuclear atypia, summary staging, primary tumor status, 











1.1 (0.8, 1.4) 




Education, race, poverty index, type of insurance, bowel 
obstruction, anatomic site, grade, histology, nuclear 
atypia, summary staging, primary tumor status, node 
positivity, distant metastasis, and surgery. 
      









0.91 (0.60, 1.38) 




Standard therapy received, year of diagnosis, race, age at 
diagnosis, sex, SEER region, marital status, median 
income, cancer site, tumor extent, nodal status, and 
histologic grade. 
      
bRobbins, et 











1.12 (1.06, 1.19) 
1.32 (1.23, 1.42) 





Insurance status, age, stage, facility type, neighborhood 
education level, and neighborhood income level. 
      
bRoetzheim, et 









1.22 (1.12, 1.32)  




Age, race, sex, marital status, insurance payer medicare, 
insurance payer nonmedicare, education level, median 
income level, place of residence, anatomic site, smoking 
status, stage at diagnosis, and treatment modality. 
aResults are for colon cancer mortality 
bResults are for all-cause mortality 





Table 2.13: Lifestyle Factors that predict All-Cause Mortality among the White/NHW 
Population 





for in Model 
Roetzheim, et 



















level, place of 
residence, anatomic 
site, comorbidity 







Table 2.14: Health System Factors that Predict Colorectal and Colon Cancer Mortality among the White/NHW Population 

















1.5 (1.1, 2.1) 
1.6 (0.9, 2.8) 
3.1 (2.4, 4.0) 
No.C Education, race, poverty index, number of 
comorbid conditions, bowel obstruction, 
anatomic site, grade, histology, nuclear atypia, 
summary staging, primary tumor status, node 
positivity, distant metastasis, and surgery. 
      
bRobbins, et 










1.77 (1.63, 1.93) 
1.59 (1.47, 1.73) 
1.76 (1.61, 1.93) 
No.C Age, stage, facility type, neighborhood education 
level and neighborhood income level and 
number of comorbidities. 










1.05 (0.91, 1.21) 
5618 
477 
Age, race, sex, marital status, education level, 
median income level, place of residence, 
anatomic site, comorbidity index, smoking 
status, stage at diagnosis, and treatment 
modality. 














1.44 (1.06, 1.97) 
1.40 (1.18, 1.67) 





Age, race, sex, marital status, education level, 
median income level, place of residence, 
anatomic site, comorbidity index, smoking 





Table 2.14: continued 




Variables Adjusted for in Model 
bRobbins, et 















0.97 (0.91, 1.04) 
 
 
0.85 (0.79, 0.91) 








Insurance status, age, stage, neighborhood 
education level and neighborhood income level, 
and number of comorbidity. 
aResults are for colon cancer mortality 
bResults are for all-cause mortality 









to those with private insurance or Medicaid. They had a higher risk (HR=1.77, CI=1.63-
1.93) for all-cause mortality than those with private insurance (HR=1.00).12 Those 
insured via Medicaid had risk ranging from HR=1.44 (CI=1.06-1.97) to HR=1.59 
(CI=1.47-1.73) for all-cause mortality than those with private insurance.12,13 
Facility type also appeared to impact all-cause mortality risk, with those treated at 
a Teaching/Research facility (HR=0.85, CI=0.79-0.91) experiencing lower risk than those 
treated at a Community Cancer program.  
 
Treatment Factors 
Cancer treatment has also been examined as a risk factor for mortality among 
non-AI/AN (Table 2.15). As expected, having surgery appears to have a large influence 
on decreased risk for CRC and colon cancer mortality.20,24 One’s risk for CRC and colon 
cancer mortality, if they do not have surgery, increases to a range of 2.5 to 5.19 times as 
those who have surgery.20,24 Results from two studies show that having adjuvant 
chemotherapy, along with surgery, decreases risk for CRC (HR=0.64, CI=0.62-0.66) and 
colon cancer mortality (HR=0.53, CI=0.50-0.56) compared to those who only had 




Cancer sites have been investigated as a predictor for mortality (Table 2.16). 
Although findings from pervious research are inconclusive in regard to tumor location 
(colon or rectum),13,19,23 Chatla and colleagues (2005) suggests that the risk for CRC 
mortality among Stage II patients is lower for rectal tumors than for the colon tumors 
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Table 2.15: Treatment Factors that Predict Colorectal and Colon Cancer and All-Cause Mortality among the White/NHW Population 














Surgery & Adjuvant 
Chemotherapy 





0.64 (0.62, 0.66) 
 
0.53 (0.50, 0.56) 
 







Race, age, sex, histological grade, anatomic 
subsite, and AJCC substage, surgery. 









0.4 (0.2, 0.7) 
31 
944 
Education, race, poverty index, type of 
insurance, number of comorbid conditions, 
bowel obstruction, anatomic site, grade, 
histology, nuclear atypia, summary staging, 
primary tumor status, node positivity, and 
distant metastasis. 
      
Redaniel, et 






5.19 (5.09, 5.30) 
121 
262 
Age, sex, stage, morphology, and 
radiotherapy. 
      
Potosky, et 









0.87 (0.70, 1.09) 
Unknown Year of diagnosis, race, age at diagnosis, 
sex, SEER region, marital status, median 
income, cancer site, tumor extent, nodal 
status, histologic grade, and comorbidities. 
      
Redaniel, et 






1.15 (1.12, 1.18) 
14,738 
121,580 




Table 2.15: continued 




















0.61 (0.55, 0.67) 
1.00 
0.96 (0.88, 1.04) 
1.00 







Age, race, sex, marital status, insurance 
payer medicare, insurance payer non-
medicare, education level, median income 
level, place of residence, anatomic site, 
comorbidity index, smoking status, and 
stage at diagnosis. 
aResults are for colon cancer mortality 













Table 2.16: Cancer Site and Size Factors that Predict Colorectal Cancer and All-Cause Mortality among the White/NHW Population 
Study Model Stratification 
Variable 




Variables Adjusted for in Model 
Chatla, et 
al. [2005]27  





0.47 (0.12, 1.87) 
70 
22 
Age, gender, Bcl-2 expression, pT 
component of stage, tumor 
differentiation, and tumor size. 





1.19 (0.37, 3.89) 
51 
15 
Age, gender, Bcl-2 expression, pN 
component of stage, pT component of 
stage, tumor differentiation, and 
tumor size. 













1.09 (1.05, 1.12) 
1.00 
1.23 (1.18, 1.28) 





Age, race, gender, sex, race X sex 
interaction term, SES, stage, 
anatomic site, grade, education. 












1.4 (1.1, 1.8) 





Education, race, poverty index, type 
of insurance, number of comorbid 
conditions, bowel obstruction, grade, 
histology, nuclear atypia, summary 
staging, primary tumor status, node 
positivity, distant metastasis, and 
surgery. 
        
Potosky, et 
al. [2002]23  






1.12 (0.92, 1.38) 
No.b Standard therapy received, year of 
diagnosis, race, age at diagnosis, sex, 
SEER region, marital status, median 
income, tumor extent, nodal status, 
histologic grade, and comorbidities. 
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Table 2.16: Cancer Site and Size Factors that Predict Colorectal Cancer and All-Cause Mortality among the White/NHW Population 
Study Model Stratification 
Variable 













0.98 (0.89, 1.09) 
7992 
1559 
Age, race, sex, marital status, 
insurance payer medicare, insurance 
payer nonmedicare, education level, 
median income level, place of 
residence, anatomic site, comorbidity 
index, smoking status, stage at 
diagnosis, and treatment modality. 
Chatla, et 
al. [2005]27 





0.52 (0.17, 1.60) 
47 
45 
Age, gender, Bcl-2 expression, tumor 
location, tumor differentiation, and 
pT component of stage. 





1.78 (0.68, 4.62) 
46 
20 
Age, gender, Bcl-2 expression, tumor 
location, tumor differentiation, and 
pT component of stage. 
aResults are for all-cause mortality 








(HR=0.47, CI=0.12, 1.87).27 It appears that there is 9% to 40% higher risk for CRC and 
colon cancer mortality if a tumor located on the right/proximal side of the colon rather 
than the left/distal.19,20  
Tumor histology has also been examined to determine if histological 
characteristics affects risk for mortality (Table 2.17). People whose tumors are classified 
as high grade or poorly differentiated tumors have a higher risk for CRC and colon 
cancer mortality than those who have low grade or well-differentiated 
tumors.19,20,23,24,27,28 Risk for CRC and colon cancer mortality ranges for those with high-
grade tumors from 1.29 to 3.48, which is at a higher risk than those with low-grade 
tumors.20,27,28 Poor tumor differentiation is also a risk for CRC and colon cancer mortality 
that ranges from 1.72 to 2.60 times higher than a tumor that is well differentiated.19,20,23 
Although results were not statistically significant, mucinous tumors may have a higher 
risk for colon cancer mortality than adenocarcinoma tumors (HR=1.40, CI=1.00-1.90).  
SEER summary stage at diagnosis has also been examined as a risk factor for 
mortality (Table 2.18). The data strongly suggest an increased risk as cancer growth 
spreads throughout the body.13,18,19,24,26 Compared to localized stage, the risk for all-
cause, CRC, and colon mortality among distant cancers are 6.95 to 11.66 times 
higher.13,18,19,24 Tumors classified as low or high grade also have the increased risk for 
colon cancer mortality at the various stages.18 The examination of year of diagnosis 
groups and stage also found an increase in CRC mortality risk as cancer spreads.26	  
 TNM staging is based on the extent of the tumor (T), the spread to lymph nodes 




Table 2.17: Histological Characteristics to Predict Colorectal and Colon Cancer Mortality among the White/NHW population 
Study Model Stratification 
Variable 




Variables Adjusted for in 
Model 
Chatla, et 
al. [2005]27  
 





3.48 (0.35, 5.21) 
82 
20 
Age, gender, Bcl-2 
expression, pT component 
of stage, tumor location, 
tumor differentiation, and 
tumor size. 





1.29 (0.50, 3.33) 
50 
16 
Age, gender, Bcl-2 
expression, pT component 
of stage, tumor location, 
tumor differentiation, and 
tumor size. 











1.41 (1.37, 1.45) 
31,386 
11,740 
Race, age, sex, histological 
grade, anatomic subsite, 
AJCC substage, surgery, 
and adjuvant 
chemotherapy. 





  Nuclear atypia 
 





1.50 (1.10, 2.10) 
3.10 (2.10, 4.70)  





Education, race, poverty 
index, type of insurance, 
number of comorbid 
conditions, bowel 
obstruction, anatomic site, 
grade, histology, nuclear 
atypia, summary staging, 
primary tumor status, node 
positivity, distant 




Table 2.17: continued 
Study Model Stratification 
Variable 





















1.15 (1.10, 1.20) 
 
1.72 (1.62, 1.82) 
 
2.15 (1.87, 2.46) 
1.36 (1.28, 1.43) 








Age, race, gender, sex, race 
X sex interaction term, 
SES, stage, anatomic site, 
grade, education. 
















1.80 (1.40, 2.50) 
 
2.60 (1.70, 3.90) 
 








Education, race, poverty 
index, type of insurance, 
number of comorbid 
conditions, bowel 
obstruction, anatomic site, 
grade, histology, nuclear 
atypia, summary staging, 
primary tumor status, node 
positivity, distant 
metastasis, and surgery. 

















1.33 (0.87, 2.02) 
 
2.26 (1.44, 3.53) 
 








Standard therapy received, 
year of diagnosis, race, age 
at diagnosis, sex, SEER 
region, marital status, 
median income, cancer 
site, tumor extent, nodal 




Table 2.17: continued 
Study Model Stratification 
Variable 



















0.20 (0.10, 0.40) 
 
 






Education, race, poverty 
index, type of insurance, 
number of comorbid 
conditions, bowel 
obstruction, anatomic site, 
grade, histology, nuclear 
atypia, summary staging, 
primary tumor status, node 
positivity, distant 
metastasis, and surgery. 













Age, sex, stage, 











Table 2.18: Summary Stage as a Risk Factor for Colorectal and Colon Cancer and All-Cause Mortality among the White/NHW 
Population 
Study Model Stratification 
Variable 















  1.00 
   
  2.72 (1.74, 4.25) 
11.61 (7.21, 18.70) 
No.e Race, age, gender, treatment 
hospital, tumor anatomic subsite, 
pathologic tumor stage and race 
X tumor grade interaction. 






  1.00 
   
  4.74 (1.74, 12.74) 
  8.35 (3.21, 21.76) 
No.e Race, age, gender, treatment 
hospital, tumor anatomic subsite, 
pathologic tumor stage and race 











  0.28 (0.24, 0.33) 
  1.00 
  2.63 (2.52, 2.75) 
11.66 (11.14, 12.20) 






Age, race, gender, sex, race X 
sex interaction term, SES, 
anatomic site, grade, education. 
Pagano, et 








  3.61c 





Age, sex, and year of diagnosis. 













Age, sex, and year of diagnosis. 













Age, sex, and year of diagnosis. 
Redaniel, et 
al. [2010]30 





  1.00 
  1.56 (1.53, 1.59) 










Table 2.18: continued 
Study Model Stratification 
Variable 
















  1.18 (0.94, 1.49) 
  1.00 
  1.98 (1.79, 2.19) 
  8.50 (7.62, 9.48) 






Age, race, sex, marital status, 
insurance payer medicare, 
insurance payer non-medicare, 
education level, median income 
level, place of residence, 
anatomic site, comorbidity index, 
smoking status, and treatment 
modality. 
aResults are for colon cancer mortality 
bResults are for all-cause mortality 
cSignificant at the p<0.0001 
dNot significant at the p<0.005 










stages ranging from I to IV, whereas summary staging, a staging system, groups cancer 
cases into five main categories: in situ, localized, regional, distant, and unknown.  
TNM Stage groupings have also been used to determine risk for mortality (Table 
2.19). Similar to summary stage, the studies examining TNM staging demonstrate 
increase in mortality risk with increasing disease severity, when risk for all-cause, CRC, 
and colon cancer mortality, in fact, increase dramatically with advancing stage, ranging 
from 1.84-3.30, 1.94-8.60, and 4.2-21.51 for Stage II, Stage III, and Stage IV, 
respectively.11,12,20,31  
One study examined long-term mortality risk and found that as a person lives 
longer, his/her risk for mortality decreases. Risk for CRC mortality is higher at all stages 
for 2-years prior to diagnosis, in comparison to those who live up to 10 years after 
diagnosis.21 When colon cancer mortality risk was examined by TNM substage, a person 
diagnosed at stage IIIC had a 2.95 times higher risk for mortality than someone 
diagnosed at substage IIIA.28 The substages (A-C) gives a more precise description of 
how invasive the cancer is; substage IIIC is more severe than substage IIIA.  
The individual TNM staging components have also been examined to determine if 
they contribute to mortality risk (Table 2.20).  The T component describes the size and 
invasiveness of the primary tumor; the higher the T number, the larger the tumor and 
growth into nearby tissues.  Being diagnosed with a primary tumor status of T4 increases 
one’s risk for CRC and colon cancer mortality from HR=1.80 (CI=1.43-2.25) to HR=19.1 
(CI=8.5-42.9).  
 The N component measures the extent of cancer spread to the lymph nodes; and 
while studies grouped the N components in a number of ways making it difficult to draw 
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Table 2.19: TNM Stage Groupings as a Risk Factor for Colorectal and Colon Cancer and All-Cause Mortality among the White/NHW 
Population 




Variables Adjusted for in Model 
aGovindarajan, 





  1.00 
  4.20 (3.20, 5.20) 
132 
184 
Age and Race. 
      









  1.00 
  1.63 (0.74, 3.59) 
  4.10 (1.92, 8.77) 





Age, gender, tumor location, tumor size, codon 72 
polymorphism, p53 mutation status. 











  1.0 
  3.3 (1.70, 6.80) 
  8.6 (4.30, 17.00) 
52.7 (26.2, 105.8) 






Education, race, poverty index, type of insurance, 
number of comorbid conditions, bowel obstruction, 
anatomic site, grade, histology, nuclear atypia, primary 
tumor status, node positivity, distant metastasis, and 
surgery. 
      








  1.00 
  2.05 (1.77, 2.39) 
  3.71 (3.24, 4.24) 





Insurance status, age, facility type, neighborhood 
education level and neighborhood income level, and 
number of comorbidities. 
      
Yan, et al. 
[2009]21  
SEER Stage 







  1.00 
  2.35 (1.84, 2.99) 
  6.72 (5.33, 8.47) 





Age, race, sex, marital status, socioeconomic status, 
tumor grade, and surgical treatment. 
 SEER Stage 







  1.00 
  1.84 (1.50, 2.25) 
  4.22 (3.48, 5.12) 





Age, race, sex, marital status, socioeconomic status, 
tumor grade, and surgical treatment. 
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Table 2.19: continued 




Variables Adjusted for in Model 








  1.00 
  1.22 (0.83, 1.79)  
  1.94 (1.30, 2.38)  





Age, race, sex, marital status, socioeconomic status, 
tumor grade, and surgical treatment. 
      
bJessup, et al. 








  1.00 
  1.75 (1.65, 1.87) 




Race, age, sex, histological grade, anatomic subsite, 























Table 2.20: TNM Staging Components as Risk Factors for Colorectal and Colon Cancer Mortality among the White/NHW Population 
Study Model Stratification 
Variable 














  1.00 
  6.37 (1.97, 20.60) 
67 
25 
Age, gender, Bcl-2 expression, tumor 
location, tumor differentiation, and 
tumor size. 





  1.00 
  0.56 (0.19, 1.60) 
34 
19 
Age, gender, Bcl-2 expression, tumor 
location, tumor differentiation, and 
tumor size. 














  1.00 
  2.10 (0.7, 5.7) 
  8.00 (3.8, 17.1) 
19.10 (8.5, 42.9) 






Education, race, poverty index, type 
of insurance, number of comorbid 
conditions, bowel obstruction, 
anatomic site, grade, histology, 
nuclear atypia, summary staging, 
node positivity, distant metastasis, 
and surgery. 








  1.00 
  1.80 (1.43, 2.25) 
156 
43 
Standard therapy received, year of 
diagnosis, race, age at diagnosis, sex, 
SEER region, marital status, median 
income, cancer site, nodal status, 
histologic grade, and comorbidities. 










  1.00 
  3.42 (1.37, 8.51) 
41 
25 
Age, gender, Bcl-2 expression, pT 
component of stage, tumor location, 




Table 2.20: continued 
Study Model Stratification 
Variable 

















  1.00 
  1.79 (1.46, 2.18) 
  3.20 (2.14, 4.76) 





Age, gender, tumor location, tumor 
size, differentiation, pT component of 
stage, pM component of TNM stage, 
and nuclear accumulation of p53. 













if <=3 or 
>=4 
Unknown 
  1.00 
  3.70 (2.7, 5.0) 
  6.80 (4.8, 9.6) 
  9.50 (5.9, 15.3) 
 
   








Education, race, poverty index, type 
of insurance, number of comorbid 
conditions, bowel obstruction, 
anatomic site, grade, histology, 
nuclear atypia, summary staging, 
primary tumor status, distant 
metastasis, and surgery. 














  1.00 
 
  1.06 (0.82, 1.38) 
  






Standard therapy received, year of 
diagnosis, race, age at diagnosis, sex, 
SEER region, marital status, median 
income, cancer site, tumor extent, 
histologic grade, and comorbidities. 








  1.00 
12.40 (9.6, 15.8) 
781 
180 
Education, race, poverty index, type 
of insurance, number of comorbid 
conditions, bowel obstruction, 
anatomic site, grade, histology, 
nuclear atypia, summary staging, 





Table 2.20: continued 
Study Model Stratification 
Variable 














  1.00 
  4.44 (2.62, 7.53) 
424 
80 
Age, gender, tumor location, tumor 
size, differentiation, pT component of 
stage, pN component of stage, and 











comparisons, they suggest that an increase in the N component increases risk for CRC 
and colon cancer mortality.20,23,27,29 According to Chatla27, et al. Stage III cases having 
N2-N3 increased ones CRC risk to 3.42 times higher than being at a N1.27  
 The Metastases component (M0-M1) has also been independently examined to 
see if this factor influences mortality risk. Individuals who were diagnosed with distant 
metastases (M1) had a high risk for CRC and colon cancer mortality ranging from 4.44 to 
12.4 times higher than those without distant metastases (M0).20,29  
 
Genetic Factors 
Genetic components have also been investigated for their affect on risk for 
mortality among the White population (Table 2.21). The Bcl-2 protein plays a role in 
tumor progression and abnormal expression of this protein has been suggested to cause 
cancer. At Stage II, those with a low Bcl-2 expression had 8.48 times higher risk for CRC 
mortality than those with high Bcl-2 expression.27 Stage III findings were not statistically 
significant, but there may be an increased risk for CRC mortality for those with low Bcl-2 
expression.27 Patients with distal adenocarcinoma and p53 accumulation results were not 
statistically significant (HR=2.06, CI=0.97-4.35).  
 It has been found that having a mutated p53 gene promotes tumor progression.  A 
mutated p53 gene has a 1.55 times higher risk of CRC mortality than not having a 
mutated p53 gene.31 Patients with proximal tumors that had nuclear p53 accumulation 
were 6.77 times more likely to die than patients who were negative for p53 
accumulation.29 
The Pro/Pro variant of the codon 72 polymorphism has an increased potential for 
cancer cell proliferation. Although the results are not statistically significant, there is 
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Table 2.21: Genetic Characteristics to Predict Risk for Colorectal Cancer Mortality for the White/NHW Population 
Study Model Stratification 
Variable 













1.31 (0.85, 2.00) 
112 
79 
Age, race, gender, TNM stage at 
diagnosis, self-rated health, 
smoking status, and receipt of 
chemotherapy. 





1.44 (0.85, 2.44) 
166 
30 
Age, race, gender, TNM stage at 
diagnosis, self-rated health, 
smoking status, and receipt of 
chemotherapy. 










0.81 (0.52, 1.30) 
0.55 (0.31-0.99) 






Age, race, gender, TNM stage at 
diagnosis, self-rated health, 
smoking status, and receipt of 
chemotherapy. 









8.48 (2.29, 31.45) 
57 
35 
Age, gender, pT component of 
stage, tumor location, tumor 
differentiation, and tumor size. 








Age, gender, pN component of 
stage, pT component of stage, 
tumor location, tumor 
differentiation, and tumor size. 









1.55 (1.04, 2.32) 
178 
195 
Age, gender, tumor location, 
tumor stage, tumor size, and 





Table 2.21: continued 
Study Model Stratification 
Variable 




Variables Adjusted for in Model 














































Age, gender, tumor location, 
tumor size, differentiation, pT 
component of stage, pN 
component of stage, and pM 













potentially increased risk for CRC mortality for the Pro/Pro variant, in comparison to 




 This review clearly uncovered a disparity in colorectal cancer research between 
AI/AN and Whites/NHW. The only risk factor explored among AI/AN is race, whereas 
among Whites/NHW, there has been a number of areas explored (Figure 2.1).  In order to 
effectively increase survival outcomes among AI/AN, it is essential to understand the risk 
factors that contribute to mortality. Therefore, recommendations for future colorectal 
cancer research among AI/AN needs epidemiological exploration in the areas of tumor 
biology/genetics, health system, lifestyle, treatment, and demographic and clinical 
factors. 
This study systematically reviewed a number of important, significant risk factors 
for mortality. However, it did not retrieve other known or suspected risk factors, 
including: body anthropometrics (height and body mass index), diet/nutrition (alcohol 
consumption, meat consumption), factors that impact treatment (transportation, access to 
treatment, social support, functional status, cognitive status, and cancer knowledge), 
prevention (colorectal cancer screening), access to treatment, and other factors (physical 
activity, use of NSAIDS, and family history).  
In this review, we found limited but suggestive evidence for geographic 
differences in mortality.13,23 Knowing that incidence rates vary by region for the AI/AN 











Another important factor that may impact risk for mortality is access to CRC screening 
and treatment. A review examining urban/rural residency13 and often urban/rural 
residency is used as a proxy for access to care. Research examining access to screening 
and treatment in AI/AN population is surely needed. This study examines how distance to 
CRC screening and treatment affects risk for mortality for AI/AN and NHW.  
 The disparity in colorectal cancer research is unfortunate, but not surprising.  
Epidemiological cancer research among the AI/AN population is a difficult task because 
many of the statistical tests require large populations for analyses. In order to examine 
multiple risk factors for survival or mortality among AI/AN, investigators must obtain 
data from population-based cancer registries to achieve enough power to detect 
significant differences.  
 Clinical data among the AI/AN population are also essential; however, there are a 
number of issues associated with the collection of data from AI/AN.  First, the small 
population size of AI/AN forces investigators to wait several years in order for the 
sample to reach sufficient size for analysis. Second, the various risk factor data must be 
obtained, including lifestyle or behavioral factors, which are not routinely collected by 
central registries. Third, working with AI/AN is challenging as communities are not 
typically located in urban centers where most cancer treatment facilities are located and 
the negative experiences with research historically, which has lead to growing mistrust 
and apprehension to participate in research. 
 An alternative to primary data collection is the utilization of cancer registry and 
administrative health data such as Medicare. The SEER-Medicare linked database 




available since 1991, but has not been fully utilized to examine cancer issues among 
AI/AN populations.  
 Utilizing SEER-Medicare data, geographic measures of urban/rural, distance to 
treatment and screening, and comorbidities will be investigated to determine their 
association with CRC mortality among AI/AN and NHW.  
Another important factor that may impact risk for mortality is access to CRC 
screening and treatment. One study in the review examined urban/rural residency13 and 
often urban/rural residency is used as a proxy for access to care. Much needed is an 
examination of access to screening and treatment but with a measure that is more precise 
than urban/rural residence. The next goal of the author will be to examine how distance to 
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THE IMPACT OF COMORBIDITY ON COLON CANCER MORTALITY  
AMONG AMERICAN INDIANS/ALASKA NATIVES  
AND NON-HISPANIC WHITES 
 
Abstract   
Comorbidity are theorized to impede cancer treatment plans, increase 
complications, decrease access to care, and can negatively impact survival. The impact of 
comorbidity on colon cancer (or colorectal cancer) mortality has been examined with a 
variety of measures and with contrasting results. When examining whether American 
Indians/Alaska Natives (AI/AN), in comparison to Whites, had an increased risk for 
colon cancer or colorectal cancer (CRC) mortality, past studies also had varying results.  
This retrospective cohort study examines the impact of comorbidity and race on 
colon cancer mortality. The AI/AN (n=490) and Non-Hispanic White (NHW; n=137,877) 
cancer cases came from the 1991-2007 SEER-Medicare linked database. Stratified by 
race, cox proportional hazards regression was utilized to determine risk factors for colon 
cancer mortality while controlling for demographic, diagnostic, and socioeconomic 
factors.  
Among NHW, the Charlson Comorbidity Index (CCI) demonstrated, as the CCI 
increased, risk for colon cancer mortality increased. A CCI of 1 had a 1.36 (CI 1.31-1.40) 
times increased risk, a CCI of 2 had a 1.66 (CI 1.57-1.75) times increased risk, and a CCI
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of 3 or more had a 2.23 (CI 2.09-2.38) times increased risk for colon cancer mortality. 
Race was an additional risk factor examined. In comparison to NHW, the data suggest 
that AI/AN have an increased risk for colon cancer mortality but results were not 
significant (H.R.=1.07, CI 0.89-1.28).  
Comorbidity impact colon cancer mortality. AI/AN appear to have an increased 
risk for colon cancer mortality but the results were not significant. There is limited 




Comorbidity is a disease or multiple diseases existing concurrently but 
independently with the primary disease of interest. Comorbidity are viewed as 
problematic with cancer care because comorbid conditions may impede cancer treatment 
plans, increase the chances of complications, and limit access to care and thus, negatively 
impact survival.1-3  
It has been found that patients with comorbidity are less likely to receive 
treatment consistent with guidelines and experience unplanned delays in treatment 
initiation.3 When looking at specific types of treatment, studies have found that patients 
with comorbidity are less likely to complete, receive, and/or initiate chemotherapy.3,4 An 
additional study found that oncologists recommend adjuvant chemotherapy for healthy, 
55-year old patients with stage III colon cancer but were less likely to recommend 
chemotherapy for younger or older patients with any comorbidity.5 There are also 
differences in radiation therapy among cancer patients with comorbidity and without. 




delays in radiation therapy initiation and patients with comorbidity are more likely to 
receive radiation therapy after a delay and less likely to receive a complete radiation 
therapy course.3 There are differing results regarding CRC patients undergoing surgery 
and whether comorbidity may impede surgery outcomes.4,6-8 Patients with significant 
comorbidity have been denied laparoscopic CRC resections9 and are more likely to 
experience complications after surgery.3 These patients are also less likely to be referred 
to a medical oncologist.3 
The impact of comorbidity on colon cancer or CRC mortality has been examined 
with innovated measures and the results have been variable. Studies that summed 
comorbidity found a slight increase for either colon cancer or CRC mortality for those 
who had comorbidites.10,11 However, the Gomez study had significant results while the 
Mayberry study did not.10,11 
Other studies used various comorbidity indices to determine its impact on colon, 
CRC, or all-cause mortality. Studies that used either the Elixhauser Index or the 
Charlson-Deyo index established an increase in index also increases one’s risk for all-
cause mortality for CRC patients.12,13 Research using the Charlson Comorbidity Index 
(CCI) found an increase in index also increases one’s risk for colon cancer or CRC 
mortality but the results were nonsignificant.14,15  
Regarding race, past studies had varying results when examining whether AI/AN 
had increased risk for all-cause, colon, or CRC cancer mortality.16-19 AI/AN demonstrated 
an increased risk for all-cause and CRC mortality but the results were not significant.16,19 
Two studies found greater risk for CRC cancer mortality among female AI/AN than 




but the results were not significant.16-19 Risk for cancer survival may be ambiguous, but 
when examining life expectancy, rates per 100,000 are lower for American 
Indians/Alaska Natives (73.6) than Whites (77.7).20 With race being a debatable risk 
factor for cancer survival, this study will also examine whether race is a risk factor for 
colon cancer survival.   
 This study utilizes the CCI to determine the impact of comorbidity on colon 
cancer mortality among AI/AN and NHW.  The impact of race (AI/AN versus NHW) on 
colon cancer mortality will also be examined.  
 
Data and Methods 
Design and Data Sources 
This study was a retrospective cohort study that examined the impact of 
comorbidity and race for colon cancer mortality among AI/AN and NHW. Data were 
acquired from the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked 
database, which is composed of the Patient Entitlement and Diagnosis Summary File 
(PEDSF), Medicare Provider Analysis and Review (MEDPAR), Carrier Claims (NCH), 
and Outpatient Claims (OUTPAT) databases. The PEDSF (1991-2007) contains the 
cancer information on diagnosed cancer cases from people residing in various SEER 
regions. These regions included the states of Connecticut, Hawaii, Iowa, New Mexico, 
California, Kentucky, Louisiana, New Jersey, Georgia, and Utah and metropolitan areas 
of Detroit and Seattle-Puget Sound. Alaska and Arizona are not included in the linked 
database. The remaining files (MEDPAR, NCH, and OUTPAT) contain various types of 






Colon cancer cases came from the SEER-Medicare linked database. Inclusion 
criteria included all ages, cancer diagnosed from 1991-2007, race (AI/AN and NHW), 
single primary of CRC cases, death not determined by autopsy or death certificate, and 
solely colon cases. Exclusion criteria were missing survival years and missing stage at 
diagnosis. The final sample size was a total of 138,367 participants with 137,877 being 
NHW and 490 being AI/AN. See Figure 3.1 for a visual of the sampling scheme.  
 
Description of Variables 
 
Survival Years 
Survival years for colon cancer were calculated in months from the date of 
diagnosis to the date of colon cancer death. The SEER date of diagnosis was used. 
Censored individuals were those who were alive at follow-up (December 31, 2009) and 
also those who died from other causes, except colon cancer. 
 
Comorbidity Index 
The CCI was used in this study.21 Comorbidity were extracted from the Medicare 
claims files (MEDPAR, NCH and OUTPAT) utilizing the SAS macro that was developed 
by SEER. The window of time to capture comorbidity is one year prior to diagnosis 
through the month of diagnosis. The macro created weighted comorbidity scores based 




Bivariate analyses (Mann-Whitney and Chi-square tests) were used to determine 








level of 0.007, was used to determine if differences had statistical significance between 
the races. The alpha level was corrected using Bonferroni’s correction using 7 
comparisons. Cox proportional hazards regression was utilized to determine risk factors 
for colon cancer mortality, while adjusting for demographics, diagnostic, and 
socioeconomic factors. SAS statistical software, version 9.2, was used for data 
management and to conduct the analyses (SAS Institute Inc., Cary, NC).  
 
Results 
 Bivariate analyses (Chi-square test, t-test, and Mann-Whitney-Wilcoxon test) 
were conducted to determine if there were any differences in demographic and clinical 
characteristics between AI/AN and NHW (Table 3.1). More AI/AN were diagnosed with 
colon cancer at a younger age. More AI/AN (34.69%) were 65 and younger than NHW 
(19.19%). AI/AN were also more likely to be single/separated/divorced (21.22%) 
compared to NHW (14.98%) but less AI/AN (23.88%) were widowed compared to NHW 
(28.96%). The median census tract income for AI/AN ($34,890) was lower than NHW 
($47,533). In order to qualify for Medicare, one must either age into the system when 
they turn 65 or if they have a disability or end stage renal disease, they qualify for 
Medicare. There were more AI/AN (24.90%) that entered the system being disabled or 
having end stage renal disease than NHW (10.67%).  
The main analyses were Cox proportional hazard regression models examining 
whether race and comorbidity impact colon cancer mortality after controlling for stage at 
diagnosis, age at diagnosis, sex, census tract income, and marital status at diagnosis 
(Table 3.2). Examining model 1, which is the model that includes both AI/AN and NHW, 
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Mean Survival Years 
(Range) 
3.65 (0-17.01) 3.90 (0-17.01) 0.1663 
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2 Window of time is 1 year prior to diagnosis through the month of diagnosis.   
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Table 3.2: Multivariate Cox Proportional Hazards Regression of Risk Factors Associated with Colon Cancer Mortality among AI/AN 
and NHW.  
 Model 1 
AI/AN & NHW 
N=138,367 
D=39,584 








Variable HR (95% CI) P-value  HR (95% CI) P-value  HR (95% CI) P-value 
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higher risk for colon cancer mortality than NHW (H.R.=1.07, CI 0.89-1.28). The CCI 
demonstrated that as one’s CCI increased, their risk for colon cancer mortality increases. 
A CCI of 1 had a 1.35 (CI 1.31-1.40) times increased risk, a CCI of 2 had a 1.65 (CI 
1.56-1.75) times increased risk, and a CCI of 3 or more had a 2.23 (CI 2.09-2.39) times 
increased risk for colon cancer mortality.  
A separate model was built for NHW but since the population is quite large in 
comparison to AI/AN, the results mimic model 1, which combines both races in the 
model. The comorbidity index for the AI/AN population has a similar risk trend as model 
1 and 2 in Table 3.2, but the results were not signification (Table 3.2, model 2).  
 
Discussion 
The impact of comorbidity on colon cancer mortality was examined and results 
demonstrated that as CCI increases, one’s risk for a colon cancer death also increases. 
Two other studies examined the affect of the increase in a CCI on CRC and colon cancer 
mortality and found similar results but their findings were statistically nonsignificant.14,15 
These nonsignificant results may have been due to a small sample sizes. 
The study population is a Medicare population that has had colon cancer and they 
do not represent the general population. This population has health care coverage through 
Medicare, whereas in the general population, not all AI/AN or NHW have health 
insurance coverage. A proportion of the population (10.13%) has end-stage renal disease 
and/or a disability. All ages were included in the study population, but this study 
population is an older population than the general United States population. 
The results demonstrate there is an association between comorbidity and colon 




has been suggested that comorbid conditions could negatively impact treatment plans, 
increase complications, and decrease access to care.1-9 Further investigation is needed to 
understand how comorbidity impact mortality outcomes. 
This study has limitations. The comorbidity measure may be underestimated. 
Comorbidity were determined by examining the month of diagnosis and 12 months prior 
to date of diagnosis and approximately 16.64% of the study population does not have a 
full year of coverage, which means they do not have a complete year of claims to 
examine. There may also be additional underestimation because not all preexisting 
secondary diagnoses are noted in the medical record, thus, they are not in the claims. 
Furthermore, some comorbid conditions may be underreported in the claims record.22 
The underestimation of comorbidity may have calculated lower comorbidity scores. The 
underestimation of comorbidity scores may also give an underestimation of risk for colon 
cancer mortality.  
The AI/AN sample is quite small and thus the study could not examine if there are 
racial differences in terms of survival. Although the 1.3 hazard ratio for the AI/AN race 
was not significant, it does suggest that there are other risk factors that may be associated 
with the AI/AN population which are impacting a higher risk for a colon cancer death in 
this population. The lack of sample size for the AI/AN population is an issue and will 
continue to be an issue because of the exclusion of AI/AN from Arizona and Alaska. 
However, it can be suggested, from the main effects model (Table 3.2, model 1), that an 






Comorbidity increases one risk for colon cancer mortality and need to be assessed 
as a risk factor. However, the process of how comorbidity impact colon cancer mortality 
is not fully understood and needs to be examined more thoroughly. The process may be 
different for various groups. For instance, race, gender, geographic residence, and other 
groups may have differential impact; the impact may be treatment plans, increase chances 
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THE IMPACT OF GEOGRAPHIC BASED ACCESS ON COLON CANCER 
SURVIVAL AMONG AMERICAN INDIANS/ALASKA  
NATIVES AND NON-HISPANIC WHITES 
 
Abstract 
Risk factors for colon cancer mortality have been studied more thoroughly in the 
White or non-Hispanic White (NHW) population, compared to the American 
Indian/Alaska Native (AI/AN). Race (AI/AN) as a risk factor has been the only factor 
examined for colon (or colorectal) cancer mortality. Results have shown an increased risk 
for AI/AN, but statistical significance has not been consistent. Geographic access using 
rural/urban measures have also been examined but with varying results. To a lesser 
extent, travel time to treatment and screening and their impact on colon cancer mortality 
has been explored and results have been inconclusive or nonsignificant.  
This retrospective cohort study examines how travel time to treatment and 
screening impacts colon cancer mortality among AI/AN and NHW. The study uses colon 
cancer cases from the SEER-Medicare linked database (1991-2007). Geographic 
Information System methodology was used to calculate travel times. Cox proportional 
hazards regression was utilized to determine risk for colon cancer mortality. 
The study found that NHW traveling 60 minutes or more to a colonoscopy or 
sigmoidoscopy screening facility, compared to living <30 minutes away, indicated
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increased risk for colon cancer mortality (HR=1.56, CI 1.16-2.09). AI/AN living 60 
minutes or more from a chemotherapy center had an increased risk for colon cancer 
mortality compared to AI/AN living <30 minutes (HR= 2.57, CI 1.39-4.76).  For NHW 
colon cancer patients at all stages, traveling 60 minutes or more had an increased risk for 
colon cancer mortality (HR=1.59, CI 1.18-2.13) than those living <30 minutes away. 
NHW living 60 minutes or more, rather than <30 minutes, to a surgical facility 
demonstrated slightly less risk for colon cancer mortality (HR=0.92, CI 0.85-0.99).  
Travel times, rather than rural/urban measures, appears to capture risk better for 
colon cancer mortality. Travel time to screening is the biggest factor in reducing colon 
cancer mortality and screening should target those having to travel further distances. 
Lower risk for colon cancer mortality for those living further from a surgical center needs 
to be explored for reasons why this is the case. For the AI/AN population, having access 
to chemotherapy appears to impact colon cancer mortality and transportation or increased 
chemotherapy facilities may help create better access. Although travel time to screening 
for the AI/AN population is not significant, the data suggest that traveling more than 30 
minutes may be a barrier for the AI/AN population. 
 
Introduction 
 Risk for colon cancer mortality has been studied more thoroughly in the White or 
non-Hispanic White (NHW) population, in comparison to the American Indian/Alaska 
Native (AI/AN) population. There have been a number of studies that have examined risk 
factors for colon cancer or colorectal cancer (CRC) mortality among NHW and have 
found demographic, clinical, lifestyle, health system, treatment, tumor biology, and 
genetic factors are associated with colon cancer mortality.1-18 When examining the 
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AI/AN studies for risk of colon cancer or CRC mortality, race was the main predictor 
explored, after controlling for various factors. These studies suggest that risk for 
mortality is higher among AI/AN than NHW.19-22 However, the results from these studies 
had statistically significant discrepancies.  
 Geographic predictors have also been examined using dichomotous measures and 
travel times to determine their affect on colon cancer or CRC survival. Rurality and 
urbanicity have been explored as a predictor for obtaining surgery,23,24 radiation, and 
chemotherapy with results suggesting that rural residents are less likely to obtain 
treatment.23,24,25 A problem with a rural/urban measure is that it can be a proxy for other 
measures. For instance, rural/urban could potentially be measuring income, education, 
travel time/distance, transportation, or all these measures and more.  
Travel time to treatment would be a more precise measure to determine its impact 
on colon cancer or CRC survival rather than a rural/urban measure. Two studies found 
travel time to radiation increases risk for death.26,27 However, another study did not find 
that increased travel impacted the odds of obtaining radiation and surgery.24 Travel time 
to CRC treatment and its affect on survival has mainly been explored in other 
countries,26-29 with one study in the United States.30 This study examines the impact of 
race and travel time to treatment and screening on colon cancer survival among AI/AN 
and NHW patients.   
 
Data and Methods 
Data Sources 
Colon cancer cases were identified in the Surveillance, Epidemiology and End 
Results Program (SEER)-Medicare linked database from 1991-2007. The SEER-
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Medicare linked database obtains cancer cases from the following geographic areas: San 
Francisco/Oakland, Detroit, Seattle, Atlanta, rural Georgia, California, Connecticut, 
Iowa, New Mexico, Utah, Hawaii, Kentucky, Louisiana, and New Jersey. The SEER-
Medicare linked database is made up of various files; this study used the Patient 
Entitlement and Diagnosis Summary File (PEDSF), Medicare Provider Analysis and 
Review (MEDPAR), Carrier Claims (NCH), and the Outpatient File (OUTPAT).  The 
1991-2008 Provider of Services (POS) files from Medicare were also utilized.  
 
Study Population 
The population consisted of 94,448 people: 94,146 were NHW and 302 were 
AI/AN. Inclusion criteria were first diagnosis of colon or rectal cancer, diagnosed during 
the 1991-2007 time period, death not determined by autopsy or death certificate, and they 
had to be NHW and AI/AN. Exclusion criteria were if they were missing any of the 
distances to treatment and screening centers, had missing survival years, missing stage at 
diagnosis, and missing geographic residence at diagnosis (rural/urban). Figure 4.1 gives 
an overview of the exclusion/inclusion criteria.  
 
Description of Variables 
 
Mortality 
 Colon cancer mortality was calculated in months from the date of diagnosis to the 
date of colon cancer death using the SEER-defined date of diagnosis and date of colon 
cancer death. Those who remained alive at last follow-up (December 31, 2009) and who 















 Rurality and urbanicity were developed using the Rural Urban Continuum Codes 
(RUCC). These codes are available in the PEDSF. The 9 RUCC were collapsed into 
metropolitan/urban and nonmetropolitan/rural. Codes 1-3 were used for urban and codes 
4-9 for rural.  
 
Travel Time to Treatment 
In order to compare results to other studies, travel time was used rather than 
distance. Three measures were developed for travel time to treatment: (1) travel time to 
chemotherapy facility, (2) travel time to radiation facility, and (3) travel time to surgical 
facility.  
Providers’ zip code areas came from the NCH file. Treatment information came 
from the NCH file. International Classification of Diseases (ICD)-9-CM codes, Healthcare 
Common Procedure Coding System (HCPCS) codes, and Current Procedural Terminology 
(CPT) codes for chemotherapy, radiation, and surgery from 1991-2007 were used to 
determine if an individual had chemotherapy, radiation, and/or surgery. (A list of the codes 
can be found in Appendix A.) Once treatment information was determined, the 
corresponding chemotherapy, radiation, and surgery zip codes were obtained from the 
NCH data. Zip code areas were mapped; one map for each treatment type. Providers’ 
addresses from the POS file were geocoded within each zip code area to provide a point for 
each treatment type.  
 Patients’ census tracts came from the PEDSF and these were mapped on each type 
of treatment map. Census tract centroids were determined using 1990 and 2010 American 
Indian (AI) census and White populations. Ten driving times from centroids to the closest 
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addresses were calculated using ESRI ArcGIS software (version 10.1) and StreetMap 
Premium for ArcGIS. Median travel times were calculated using travel times to facilities 
that were in existence during patients’ year of diagnosis. 
To illustrate travel times development, see Figure 4.2. Travel times were calculated 
between a patient’s census tract centroid and up to 10 closest travel times. As an example, 
suppose D2, D6, and D8 treatment facilities were not in existence during the patient’s 
cancer diagnosis. The calculations of median travels would use the travels times of D1, D3, 
D4, D5, D7, D9, and D10 in the calculation.  
 
Travel Time to Potential Screening 
 Travel times for potential screening (colonoscopy or sigmoidoscopy) were 
calculated in a similar manner. Addresses for Medicare screening facilities were 
unavailable, so treatment addresses were used as a proxy for screening facilities. Providers’ 
zip code areas were determined in the same manner as above, but screening billing codes 
were used instead of treatment codes. These codes can be found in Appendix B. The final 
variable for screening used the closest travel time for either a colonoscopy or 
sigmoidoscopy travels times.  
 
Statistical Analysis 
The data were analyzed using SAS 9.2 (SAS Institute Inc, Carry, NC, 2001). 
Bivariate analyses were used to assess statistical differences between AI/AN and NHW 
for the demographic, clinical characteristics, and geographic measures. Multiple 
comparisons were conducted. Hence, significance was adjusted using Bonferroni’s 




Figure 4.2: Diagram of Potential Travel Times to Treatment or Screening Facilities.  
 
colon cancer mortality.  
 
Results 
 Three main analyses were conducted for this study. First, bivariate analyses (Chi-
square test, T-test, or Mann-Whitney-Wilcoxon test) of demographic, socioeconomic, 
and clinical characteristics were used to determine if there were any differences between 
AI/AN and NHW. The second analysis examined the impact of travel times to treatment 
and screening on colon cancer mortality using cox proportional hazards modeling. Third 
was the examination of the effect of travel times to treatment and screening based on the 




Demographic and Clinical Comparisons 
Bivariate analyses for demographic, socioeconomic, clinical characteristics, and 
travel times for colon cancer patients can be found in Table 4.1. The mean age at 
diagnosis was younger for AI/AN (69.88%) patients than NHW (74.44%) patients. (Mean 
age was the same as the median age.) More AI/AN (21.52%) were single or separated or 
divorced than NHW (14.62%). NHW (52.29%) were more likely to be married than 
AI/AN (44.04%) and more NHW (29.08%) were widowed than AI/AN (26.49%). 
Median census tract income for AI/AN patients ($35,428) was lower than NHW patients 
($47,288).  
In order to qualify for Medicare, one must qualify by age (65 or above) or have a 
disability and/or end stage renal disease. There were more NHW patients (89.37%) that 
qualified for the Medicare program by age than AI/AN patients (77.15%). More NHW 
patients (83.78%) resided in urban areas than AI/AN (72.52%). And, most of the 
population resided in urban areas at cancer diagnosis than in rural areas.  
Travel time to a chemotherapy, radiation, and surgical facility was greater for 
AI/AN colon cancer patients. More AI/AN (31.13%) had 60 minutes or more to access a 
chemotherapy facility than NHW (18.49%). In comparison to NHW patients (7.79%), 
AI/AN colon patients (13.25%) had to travel 60 minutes or more to a radiation facility. 
Larger percentage of AI/AN (10.26%) also had 60 minutes or more to travel to a surgical 
center than NHW (03.11%). AI/AN colon cancer patients (00.66%) had slightly increased 













    











    
Mean Age at Diagnosis1 
(Range) 
69.88 (28-98) 74.44 (22-106) <0.0001 
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Reason for Entitlement 
Age 

























    
Cause of Death 
Alive 
Colon Death 
Other Cancer Death 














                                            
1 Mean age is the same as the median age. 
2 Wilcoxon Test, two-sided (z= -18.7972) 
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Mean Survival Years (Range) 3.67 (0-16.92)  3.95 (0-17.01)  0.2214 
    
Charlson Comorbidity Index3 
                                      0 
                                      1 














    















    
Travel Time to Chemotherapy 
< 30 minutes 












    
Travel Time to Radiation 
< 30 minutes 












    
Travel Time to Surgery 
< 30 minutes 












    
Travel Time to Screening 
< 30 minutes 















                                            
3 Window of time is 1 year prior to diagnosis through the month of diagnosis.   
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Race and Colon Cancer Survival 
 Table 4.2 contains results for geographic measures that may impact colon cancer 
mortality. Model 1 included both NHW and AI/AN and this model controlled for stage, age, sex, 
income, marital status, race, and comorbidity index. Model 2 was developed for the AI/AN 
population and model 3 was for NHW and they both had the same controls as Model 1, except 
for race.  
Examining whether there were differences among race, the NHW model (model 3) found 
that travel time to screening was significant for this model. Traveling 60 minutes or more, in 
comparison to <30 minutes, to a colonoscopy or sigmoidoscopy screening facility indicated 
increased risk for colon cancer mortality among the NHW (HR=1.56, CI 1.16-2.09), whereas for 
AI/AN, screening and risk for colon cancer mortality was not statistically significant. In regards 
to AI/AN, it appears there is increased risk for colon cancer mortality for AI/AN living 60 
minutes or more from a chemotherapy center (HR= 2.57, CI 1.39-4.76) (Model 2). Results for 
travel to chemotherapy for the NHW population was not statistically significant. 
 
Stage, Race, and Colon Cancer Mortality 
 Tables 4.3, 4.4, and 4.5 are stage-specific models and in combination with travel time to 
appropriate treatment and screening. For instance, those only at distant stages should only be 
obtaining radiation treatment. Therefore, models (Table 4.4) were created for only those with 
distant stages and travel times to a radiation and screening center.  
Table 4.3 includes results for those at regional and distant stages and the impact travel 
times to chemotherapy and screening centers have on colon cancer mortality. Model 1 includes 
both the AI/AN and NHW, Model 2 is AI/AN, and model 3 is NHW. Results show NHW living 
60 minutes or more, in comparison to those who are living 30 minutes or less, from a screening
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Table 4.2: Multivariate Cox Proportional Hazards Regression of Risk Factors Impacting Colon Cancer Mortality among AI/AN and 
NHW. 
  Model 1 











Variable Attribute HR (95% CI) 
N=94,448 
P-Value HR (95% CI) 
N=94,146 
P-value HR (95% CI) 
N=302 
P-value 























        
Age at Diagnosis  1.03 (1.03-1.03) <0.0001 1.04 (1.01-1.07) 0.0029 1.03 (1.03-1.03) <0.0001 















        
CT Income  0.99 (0.98-0.99) 0.0002 0.87 (0.71-1.07) 0.1900 0.99 (0.98-0.99) 0.0002 
        




























        
CCI 0                             






























                                            
4 Single, separated or divorced. 
a For Model 2, the sample size was 2 for the >=60 min category. The individual was included in the <60 min category. 
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Table 4.2: continued 
  Model 1 











Variable Attribute HR (95% CI) 
N=94,448 
P-Value HR (95% CI) 
N=94,146 











    

















        
























        
























        
























        




























Table 4.3: Multivariate Cox Proportional Hazards Regression of the Impact of Travel Time to Chemotherapy, Surgery, and Screening 
on Colon Cancer Mortality by Regional and Distant Stages. 
  Model 1 

















































        
Age at Dx  1.03 (1.03-1.04) <0.0001 1.05 (1.01-1.08) 0.0110 1.03 (1.03-1.04) <0.0001 

















        
CT Income  0.98 (0.97-0.99) 0.0002 0.80 (0.62-1.04) 0.0972 0.98 (0.97-0.99) 0.0003 































        
aCCI6 
 
0                             


























                                            
5 Single, separated or divorced. 
6 Window of time is 1 year prior to diagnosis through the month of diagnosis.   
a For model 2, the sample size was 5 for the 3+ category. These 5 people were included in the 2 category. 
B For model 2, the sample size was 1 for the >=60 min category. The individual was included in the <60 min category.  
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Table 4.3: continued 
  Model 1 










































        
























        























        





























Table 4.4: Multivariate Cox Proportional Hazards Regression of the Impact of Travel Time to Surgery and Screening on Colon Cancer 
Mortality by Distant Stage. 












  HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value 
Age at Dx  1.03 (1.03-1.04) <0.0001 1.17 (1.06-1.30) 0.0017 1.03 (1.03-1.04) <0.0001 

















        
CT Income  0.97 (0.95-0.99) 0.0001 0.76 (0.45-1.27) 0.2903 0.97 (0.95-0.99) 0.0001 































        
aCCI8 
 
0                             

























































                                            
7 Single, separated or divorced. 
8 Window of time is 1 year prior to diagnosis through the month of diagnosis.   
a For model 2, the sample size was 3 for the 3+ category. These 3 people were included in the 2 category. 
B For model 2,, the sample size was 2 for the <60 min category and 0 for the >=60 min category. The potential screening variable was dropped for Model 2.   
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Table 4.4: continued 































































Table 4.5: Multivariate Cox Proportional Hazards Regression of the Impact of Surgery and Screening Travel Times on Colon Cancer 
Mortality by All Stages. 
  Model 1 











  HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value 



































        
Age at Dx  1.04 (1.03-1.04) <0.0001 1.05 (1.02-1.08) 0.0002 1.04 (1.03-1.04) <0.0001 

















        
CT Income  0.99 (0.98-0.99) <0.0001 0.86 (0.70-1.06) 0.1513 0.99 (0.98-0.99) <0.0001 































        
CCI10 
 
0                             




























                                            
9 Single, separated or divorced. 
10 Window of time is 1 year prior to diagnosis through the month of diagnosis.   
a For model 2,, the sample size was 2 for the >=60 min category. The 2 people were added into the <60 min category.   
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Table 4.5: continued 
  Model 1 































































































center increases one’s risk for a colon cancer death for those at regional or distance stages (HR= 
1.60, CI 1.09-2.35). As for AI/AN, the results were not significant for travel time to 
chemotherapy. More importantly for the AI/AN, travel time to chemotherapy was more of an 
impact. In comparison to living 30 minutes or less, AI/AN living 60 minutes or more to a 
chemotherapy center had an increased risk for colon cancer mortality (HR=2.43, CI 1.03-5.77).  
Table 4.4 displays results of those at distant stage and travel times to a radiation and a 
screening center and their risk for colon cancer mortality. For all the models, none of the 
geographic measures were significant.  
Results for risk for colon cancer mortality among those at all stages and travel times to 
surgery and screening centers can be found in Table 4.5. Results in model 3 demonstrate less risk 
for colon cancer mortality among NHW living 60 minutes or more to a surgical center than those 
living less than 30 minutes (model 3) (HR= 0.92, CI 0.85-0.99). There is also increased risk for 
colon cancer mortality among NHW at all stages and living 60 minutes or more from a screening 
facility than those living less than 50 minutes (HR= 1.59, CI 1.18-2.13). The results for the 




 In terms of risk for colon cancer mortality, the effects of travel time to treatment and 
screening have not been fully investigated, especially among AI/AN. Furthermore, risk factor 





Rural/Urban, Travel Time, and Access 
 Many cancer studies often use rural/urban residence as a variable to examine geographic 
access. However, in all the combined race models (Models 1 in Tables 4.2, 4.3, 4.4, and 4.5), 
after controlling for various risk factors, geographic residence was not significant and for the 
models, the relative risk for rural, in comparison to urban, hovered around 1.00. Models were 
also built excluding travel times and rural status, in comparison to urban status, was not 
significant and relative risks also hovered around 1.00 (results were not presented.) In this study, 
both rural and urban residents had travel times in all three travel time strata: <30, 30-60 and 60+ 
minutes. It appears that using travel times is a more accurate measure than using rural/urban 
measures. Furthermore, using travel times to treatment and screening gives a more accurate 
picture to which type of service may be most important for a population, rather than using 
rural/urban measures.  
 
Race and Colon Cancer Mortality 
 AI/AN who live 60 minutes or more to the nearest chemotherapy center have an elevated 
risk for colon cancer mortality (Table 4.2). Therefore, it appears there is a difference in colon 
cancer survival between AI/AN and NHW who have to travel 60 minutes or more for 
chemotherapy services. AI/AN may have a more difficult time accessing chemotherapy 
treatment and/or following through on treatment compliance, which may be due to lack of 
transportation and/or road conditions. AI/AN living on reservations may also have a more 
difficult time traveling during winter months, especially if they live a distance from an asphalt 
road.  
 Models 1 in Tables 4.2-4.4 include race (AI/AN and NHW) as a risk factor for colon 
cancer mortality. Each of these models suggests AI/AN have an increase risk for colon cancer 
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mortality after controlling for a number of factors, in comparison to NHW. However, in each 
model, the results were not statistically significant, which may be due to a small sample size for 
AI/AN. The issue of race as a risk factor needs to be explored further. Other studies have found 
disparities in cancer treatment among races and these differences were to treatment, biology, and 
knowledge/beliefs.13,31-41 The issue of small sample size will always be an issue since the AI/AN 
population will always be smaller than NHW, so exploration of race might continue to be a 
problem.  
 
Stage and Colon Cancer Mortality 
 The models that examine the impact of travel times to treatment and screening by various 
stages can be found in Tables 4.3-4.5. When examining the models, there are not only 
differences by race but also stage at diagnosis.  
For AI/AN at regional and distant stages, having to travel 60 minutes or more to obtain 
chemotherapy negatively impacts their survival (Table 4.3, Model 2), whereas for NHW, travel 
time to chemotherapy did not impact their survival. These results need to be explored more 
thoroughly to understand the mechanism(s) that are influencing poor survival among the AI/AN 
population who are at regional and distant stages and having to travel 60 minutes or more to 
obtain chemotherapy.  
 For NHW at all stages, distance to screening and surgery had the largest impact on 
survival for them (Table 4, Model 3). Therefore, the data suggest that 6o minutes or more of 
driving time to screening negatively impacts colon cancer mortality. A diagnostic or treatment 
colonoscopy is an involved process and if you have a long travel time, the preparation and 
procedure may potentially be a barrier for a colonoscopy.  
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 Results also indicate that those living 60 minutes or more from a surgical center are 7% 
less likely at risk for a colon cancer death. Decreased risk may be due to surgical practices or 
differences in patients in rural areas. It has been found that rural surgeons performed more 
endoscopic procedures than urban surgeons and this surgical experience may decrease 
complications and/or death.42 An additional study found that complications and reoperation rates 
were higher in urban centers than rural centers and that urban centers had sicker patients.43 
Higher complications, reoperation rates, and sicker patients may contribute to higher death in 
urban areas. Surgical procedures might also be different for rural or for patients living a distance 
from a surgical center. For instance, in a breast cancer study, it was found that those living 




The population is a Medicare population and they have different characteristics than the 
general population. This study population potentially has more urban elderly and they live in 
more affluent areas, suggesting a higher income population.45 Since this population is a Medicare 
population, they have Medicare coverage, whereas many in cancer patients do not have 
coverage.  
There may be underestimation of treatment distances for the AI/AN population. 
Reservations do not have street addresses and many AI/AN obtain mail from their nearest post 
office. For this study, patient’s census tracts are determined from zip codes and post offices are 
located in areas that have a larger concentration of people. Most likely, some of the areas that 
have post offices also have a health provider that may (or may not) provide treatment and 
screening procedures.  
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The screening travel times are also most likely underestimated. The centroids were 
determined using the addresses of treatment providers within the zip code areas of providers 
offering screening procedures. This method would overestimate screening providers and thus 
would increase screening facilities for all. This might be more problematic in less populated 
areas since the census tracts and zip code areas are larger in less populated areas.  
 
Conclusion 
 Travel time rather than rural/urban status gives a better picture to determine risk for colon 
cancer mortality. Living 60 minutes or more to obtain screening is risk for colon cancer mortality 
across various stages for the NHW population. Access to screening may need to be targeted for 
those who have to travel longer distances rather than targeting whether a person lives in a rural 
or urban area.  Further travel time to a surgical center appears to show a slightly lower risk for 
colon cancer mortality. However, this lower risk needs to be explored further to determine if 
there are differences in those further for surgical procedures. Chemotherapy access needs to be 
further explored and addressed for AI/AN having to travel further distances. Chemotherapy is 
not a one-time treatment and it may be extremely difficult for those living further to access this 








Table 4.6: Medicare claims codes for surgery, radiation and chemotherapy.  
Author Years Surgery  Radiation Chemotherapy 






  J0640, J9190, 96408-96414, 
96520, 96530, 96545, 96549, 
Q0083-Q0085, E0781, 
E933.1, V58.1, V66.2, 
V67.2, 99.25 
Baldwin, et al.47  Patients: 1992-1996 
Claims: 1991-1997 
 77261-77499, 77750-77799, 
V58.0, V66.1, V67.1, 92.20-
92.29, 0330, 0333, 0339 
 
Bradley, et al.48 Patients: 1997-2000 
Claims: 1997-2001 
  96400-96599, Q0083-
Q0085, J0640, J8510, J8520, 
J8521, J8530-J8999, J9000-
J9999, E0781, E9331, V58.1 
Cen, et al.49 Patients: 2003-2005 
Claims: 2003-2006 
 
  96400–96549, J8510, J8520, 
J8521, J8530–J8999, J9000–
J9999, Q0083–Q0085, 9925, 














Table 4.6: continued  
Author Years Surgery  Radiation Chemotherapy 
Cheung, et al.50  Patients: 1991-2002 
Claims: 1991-2003 
 77xxx, 79xxx, S8049, V58.0, 
92.2X, 0330, 0333, 0339 
 
964XX, 9651X-9654X, 
C1166, C1167, C1178, 





J7150, J85xx-J87xx, J9xxx, 
J8999, Q0083, Q0085, 
S9325-S9329, S933x-S937x, 
S9494-S9497, V58.1, 99.25, 















Q0083-Q0085, 99.25, V58.1, 






  C9205, J8520, J8521, J9190, 
J9206, J9263 
Dobie, et al.54  Patients: 1992-1996 
Claims: 1991-1998 
  96408, 96410, 96412, 96414, 
96520, 96530, 96545, 96549, 
J0640, J9190, Q0083-Q0085, 





Table 4.6: continued  
Author Years Surgery  Radiation Chemotherapy 
Dobie, et al.55  Patients: 1992-1999 
Claims: 1992-2004 
 77331-77334, 77336, 77370, 
77399, 77402-77417, 77419-
77431, 77499, 92.20, 92.23-
92.36, 92.29, V58.0, 0333 
96408, 96410, 96412, 96414, 
96545, 96549, 96520, 96530, 
J0640, J9190, Q0083-Q0085, 
99.25, E0781, V58.1  
Du, et al.56  Patients: 1992 
Claims: 1991 
 77401–77499 or 77750–
77799, 9221-9229, 0330, 
0333  
 
Du, et al.57 Patients: 1991-1992 
Claims:  
  9925, 96400- 96549, 0331, 
J9000-J9999, Q0083-Q0085, 
V58.1, V66.2, V67.2 










44160, 44204-44212, 44300, 
44310, 44320, 44322, 44340, 
44345, 44346, 44312, 44314, 
44316, 44605, 44620-44626, 
45005, 45020, 45100, 45108, 
45110–45135, 45395-45397, 
45562, 46020, 46030, 6040-
46060, 46080, 46083, 46200, 
46210, 46211, 46220, 46221, 
46230, 46250-46262, 6270-
46288, 46320, 46500, 46700, 
46706, 46750-46762, 6900-
46924, 46934-46936, 46940, 





Table 4.6: continued  












44140, 44141, 44143- 44146, 
44153, 44155, 44156, 44160, 
45110, 45111, 45113, 45116, 
45119, 45130  
  
Gross, et al.62 Patients: 1992-2002 44140-44147  77400-77499, 77750-77799, 




Howard, et al.63  Patients: 1995-2005 
Claims: 1995-2006 
  964XX, 965XX, Q0083-
Q0085, G0355, G0359, 
V58.1, V66.2, V67.2, 99.25 
Keating, et al.64 Patients: 2001-2004 
Claims:  
44110, 44111, 44140-44160, 
44392, 44393, 44394, 5110-
45121, 45126, 45160-45170, 
45190, 45308, 45309, 45315, 
45320, 45333, 45338, 45339, 
45383-45385, 45.41-45.42, 
45.60, 45.71-45.76, 45.79-
45.89, 46.04, 48.35, 48.36, 
48.40, 48.41, 48.49-48.69 
77261-77431, 77499, 77750-
77797, 92.2-92.29 V58.0, 
V67.1, V66.1, 0330, 0333 
 
30070, 50145, 50146, J9190, 
J8520, J8521, 99.25 
 
Lang, et al.65 Patients: 1991-2000 
Claims: 1991-2005 
 
 77401-77499, 77750-77799, 
V58.0, V66.1, V67.1, 92.21-
92.29 
 
51720, 964xx, 965xx, J7150, 
J8510, J8520, J8521, J8530-
J8999, J9000-J9999, Q0083-





Table 4.6: continued  
Author Years Surgery  Radiation Chemotherapy 




  J8520, J8521, J9035, J9055, 
J9190, J9206, J9263, C9205, 
C9214, C9215, C9257, 
Q2024, S0116, V58.1, 





  J8520, J8521, J9035, J9055, 
J9190, J9206, J9263, J9303, 
J9999, C9215, C9235 
Obeidat, et al.68  Patients: 1998-2002 
Claims:  
32440, 32442, 32445, 32480, 
32482, 32484, 32500, 32520, 
44139-44160, 44204-44213, 
45110-45126, 47120-47130, 
47300, 47380-47382, 51597, 
58240, 45.70, 45.80, 48.40-
48.60 
77401-77799, 92.21-92.29, 
V58.0, V66.1, V67.1, 0330, 
0333, 0339 
 
964xx, 965xx, 51720, 0331, 
0332, 0335, 99.25, J0640, 
J8510, J8520, J8521, J8530-







 77401-77499, 77750-77799, 
V58.0, V66.1, V67.1, 92.21-
92.29, 0330, 0333 
 
C8953-8955, E0781, E9331, 
G0355-G0363, J0640, J8510, 
J8520, J8521J8530-J8999, 
J9000-J9999, J9190, J9200, 
J9206, J9263, Q0177, 
Q0083-Q0085, S9329-9331, 
V58.1, V66.2, V67.2, 99.25. 





Table 4.6: continued  
Author Years Surgery  Radiation Chemotherapy 
Paulson, et al.70  Patients: 1996-2003 44140, 44141, 44143-44147, 
44150, 44152, 44155, 44160, 
44204-44208, 44210, 44212, 
45110-45114, 45116, 45119, 
45123, 45126, 45160, 45170, 
45395, 45397, 45.70, 45.71, 
45.72, 45.73, 45.74, 45.75, 
45.76, 45.79, 45.80, 48.35, 
48.40, 48.41, 48.49, 48.50, 
48.60, 48.61, 48.62, 48.63, 
48.64, 48.65, 48.69 
  
Wright, et al.71 Patients: 1995-2005 
Claims: 




  77401-77499, 77520, 77523, 
77750-77799, G0256, 
G0261, V58.0, V66.1, 
V67.1, 92.21-92.29, 0330, 
0333 
51720, 964xx, 96400-96549, 
Q0083-Q0085, V58.0, 















Table 4.7: Medicare claims codes for colonoscopy and sigmoidscopy. 
Author Years Colonoscopy Screening Sigmoidoscopy Screening 
Benarroch-




44388, 33489, 44392, 44393, 44394, 45394, 
45378, 45380, 45382, 45383, 45384, 45385 
G0105, G0121, 45.23, 45.25, 45.27, 45.41, 
45.42, 45.43, 48.36 
 
Cooper & Kou.73  Sample: 1998 
Claims: 1993-
1998 
44388, 44389, 44392, 44393, 44394, 45378, 
45380, 45382, 45383, 45384, 45385, G0105, 
G0121, 45.23, 45.25, 45.41, 45.42, 45.43, 
48.36 
45330, 45331, 45333, 45338, 45339, G0104 
Fenton, et al.74  Sample: 1995-
2003. 
Claims: 
45378, 45380, 45382, 45383, 45384, 45385, 
G0105, G0121, 45.21-45.23, 45.25 
45300, 45305, 45308, 45309, 45315, 45317, 
45320, 45330, 45331, 45333, 45334, 45338, 
45339, G0104, 45.24, 48.23, 48.24 
HHS Guide75 Claims: 1/2005-
12/31/2006 
G0105, G0121 G0104 
HHS Guide76 1/2007-
12/31/2008 
G0105, G0121 G0104 
HHS Guide77 1/2009-
12/31/2010 
G0105, G0121 G0104 
Khiani, et al.78  Sample: 2001-
2005 
 
44388, 44389, 44392, 44393, 44394, 45378, 
45379, 45380, 45382, 45383, 45384, 45385,  
45.23, 45.25, 45.41-3, 48.36 
45300-45327, 45330-45342, 45345, G0104,  
45.24, 48.21-4 




44388-44394, 44397, 45355, 45378-45387, 
G0105, G0121 
 
45300, 45303, 45305, 45307, 45308, 45309, 
45327, 45330, 45331, 45332, 45333, 45334, 
45337, 45338, 45339, 45340, 45341, 45342, 
45345, G0104, 45.24, 45.42, 48.21-48.25 
Semrad, et al.80  Sample: 2003 
Claims: 1998-
2005 
45378, 45380, 45382, 45383, 45384, 45385, 
G0105, G0121, 45.23, 45.25, 45.42, 45.43, 
48.36 
45300, 45305, 45308, 45309, 45315, 45317, 
45320, 45330, 45331, 45333, 45334, 45338, 
45339, G0107, 45.24, 48.23, 48.24 
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Table 4.7: continued 
Author Years Colonoscopy Screening Sigmoidoscopy Screening 
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 The overall purpose of the study was to determine colon cancer risk factors 
among American Indians/Alaska Natives (AI/AN) and Whites/Non-Hispanic Whites 
(NHW). Risk factors for colon cancer mortality were determined by utilizing current 
literature and through the development of a study that specifically examined the impact 
of race, comorbidities, travel time to screening, and travel time to treatment. 
 
Race 
 The systematic review revealed that race was the only risk factor explored among 
American Indians/Alaska Natives (AI/AN) and the majority of the results were not 
significant, but all suggested an increased risk for colorectal or all-cause mortality among 
AI/AN. Risk ranged from HR = 1.10-1.50 (Table 2.4), whereas in the White population, 
numerous risk factors impacting colon cancer mortality have been investigated more 
thoroughly.  
 Race was examined in Chapters 3 and 4 and the hypothesis was to show an 
increased risk for colon cancer mortality among AI/AN. The results indicated increased 
risk for AI/AN, after controlling for various covariates, but results were nonsignificant. 
The range of risk for colon cancer mortality among AI/AN ranged from HR=1.06-1.18 
(Tables 3.2, 4.2-4.5). Results being nonsignificant most likely is due to the smaller 
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sample size of AI/AN, in comparison to the NHW population. The increased colon 
cancer risk for AI/AN suggests that there may be other factors impacting race 
differentially and this needs to be further explored among AI/AN.  However, sample size 
will always be an issue with the AI/AN population and it will continue to be an issue to 
detect effects of race. 
 
Cormorbidity 
Studies have examined the impact of comorbidity on colon cancer, colorectal 
cancer, or all-cause mortality.1-4 Various comorbidity measures were used in these studies 
and their findings support the findings in this dissertation. An increase in comorbidity 
measure has a negative impact on colon cancer survival. Although not every study had 
statistically significant results, the risk for colon cancer, colorectal cancer, or all-cause 
mortality increased as comorbidity measure increased.  
The hypothesis was to demonstrate an increase risk for colon cancer mortality 
among those with comorbidities. The results found NHW whose comorbidity index 
increased had an increased risk for colon cancer mortality (Table 3.2, Model 3). The 
NHW results were statistically significant. Results for the AI/AN were not statistically 
significant. Nonsignificance for AI/AN was most likely due to small sample size.  
 
Travel Time to Treatment and Screening 
 The examination of travel times to treatment (colonoscopy, radiation, and 
surgery) and travel time to screening (colonscopy and sigmoidoscopy) and their impact 
on colon cancer mortality were also examined. The hypothesis of the study was for 
increased risk for colon cancer mortality for those traveling longer distances to treatment 
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and screening. The NHW model (Table 4.2, Model 3) demonstrated that those traveling 
60 miles or more, rather than those traveling less than 30 minutes, to a screening facility 
had increased risk for colon cancer mortality. For AI/AN traveling 60 minutes or more, 
rather than those traveling less than 30 minutes, to a chemotherapy center had an 
increased risk for colon cancer mortality (Table 4.2, Model 2).  
The examination of treatment and screening by various stages had different 
results. NHW traveling more than 60 minutes to screening and who were at regional or 
distant stage had higher risk for colon cancer mortality than NHW at regional or distant 
stage and traveling less than 30 minutes. Results for AI/AN at regional and distant stages 
were different than the NHW regional and distant stages (Table 4.3). AI/AN traveling 
more than 60 minutes to chemotherapy had an increased risk for colon cancer mortality, 
than AI/AN traveling less than 30 minutes.  
The all stages models indicated that distance to screening was the most important 
factor for NHW.  An additional result, which had contradictory findings, was distance to 
surgery. NHW at all stages who had to travel 60 minutes or more to screening had an 
increased risk for colon cancer mortality than NHW who traveled less than 30 minutes 
(Table 4.5, Model 3). NHW at all cancer stages who had to travel 60 minutes or more to 
surgery had lower risk for colon cancer mortality than who traveled less than 30 minutes.  
 These results represent the importance of examining data by race and stage along 
with race. There is definitely a differential in access for AI/AN and NHW and by cancer 
stage. The results for the AI/AN population suggest that access to chemotherapy for those 
living 60 miles or further needs to be explored further. What makes this population 
unique that it impedes chemotherapy uptake or compliance? Furthermore, for NHW the 
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issue appears to be access to screening. Those living further away appear to have 
problems with uptake of screening. This most likely is also an issue for the AI/AI 
population and it would benefit our communities if outreach activities targeted those 
living further away. And NHW living further from a surgical center having less risk need 
further exploration. Are there benefits to living further away?  
 
Summary 
There have been few studies that have examined travel time to treatment 
(radiation and surgery) and to the author’s knowledge, no studies examining travel time 
to screening. Travel time to CRC treatment and its impact on survival has mainly been 
explored in other countries,5-8 with one study in the United States.9A couple of studies 
found increased travel time to radiation increased one’s risk for death.5,6 Another study 
did not find increased travel impacting the risk of obtaining radiation and surgery, which 
in turn would impact survival.10 This study offers new findings of increased travel time to 
various types of treatment (chemotherapy, surgery, and radiation) and to screening and 
their impact colon cancer mortality.  
Comorbidities as a risk for colon cancer or CRC mortality have been examined 
with novel measures and had varying results regarding statistical significance.1-4,11,12 
These studies summed comorbidities or used various indices (Elixhauser, Charlson-Deyo, 
and Charlson comorbidity index). Studies using the Charlson comorbidity index (CCI) 
found an increase in index also increases one’s risk for colon cancer or CRC mortality, 
but the results were nonsignificant.2,13 This study adds to using CCI and these findings 
were statistically significant and demonstrated that an increase in the CCI also increases 




 The limitations of this study are in regards to the Medicare population, 
comorbidity measure, race, travel time to treatment, and travel time to screening. This 
study cannot be generalized to the general public since it is a Medicare population with 
cancer. The Medicare population has different characteristics than the general population: 
more urban elderly, more affluent, and Medicare insurance coverage.  
The comorbidity measure is potentially underestimated. Having an 
underestimation of comorbidities would create lower comorbidity scores. The 
underestimation of comorbidity scores may also give an underestimation of risk for colon 
cancer mortality.  
 The AI/AN sample is small, in comparison to the NHW population. Thus, the 
study did not have statistical significance for many of the risk factors that were examined. 
However, even though there was increased risk for the AI/AN race and it was not 
significant, it does suggest that there is potential increased risk for AI/AN. The lack of 
sample size for the AI/AN population is an issue and will continue to be an issue because 
of the exclusion of AI/AN from Arizona and Alaska from the SEER-Medicare database.   
 Treatment travel times may be underestimated for the AI/AN population living on 
reservations. Many reservations do not have street addresses and their location was 
determine by postal zip codes, which most likely will be nearer to a health provider 
providing treatment and screening procedures.  
There may be also an underestimation of screening travel times. In order to 
determine a centroid within a screening provider’s zip code area, centroids were 
determined using the addresses of treatment providers. This method would overestimate 
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screening providers and thus would increase screening facilities for all. This might be 
more problematic in less populated areas since the census tracts and zip code areas are 
larger in less populated areas.  
 
Strengths 
The strengths of this study are in regards to type of database, number of cases, 
claims data, type of data, and geographic locations. This SEER-Medicare database is a 
population database. Therefore, this database includes all the colon cancer patients with 
Medicare coverage. The database also includes a large number of cases, which is 
favorable for survival study. The data are also longitudinal from time of Medicare 
coverage until death; the data are rich in information over time. The database also has a 
diverse geographic area across the nation, including both urban and rural participants.  
 
Conclusion 
 There are differences in risk factors for colon cancer survival between NHW and 
AI/AN. These differences need to be considered when taking survival improvements into 
consideration for each population. Comorbidities are also an issue for colon cancer 
patients and additional studies need to examine the mechanism(s) of how comorbidities 
influences poor survival.  
 Additional research includes examining the impact of comorbidities and travel 
times to screening and treatment impacts rectal cancer. Also, examining the density of 
treatment providers and determining if density of providers impacts survival is necessary. 
And, understanding the decision-making process of NHW and AI/AN and uncovering the 
influences participating (or not) in a colonoscopy and examining the data based on travel 
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times to screening facility is needed. A similar study is also needed in examining the 
decision process of chemotherapy treatment compliance. Screening is often encouraged 
to obtain early detection and thus, improving survival. And, it appears that NHW (and 
possibly AI/AN) living a distant away need assistant in obtaining screening. However, it 
appears that in the AI/AN population, uncovering factors influencing chemotherapy 
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